制药验证文件-洁净压缩空气GMP评估(英文版)
EUGMP-中英文对照[1]
EU GMP ANNEX 1 MANUFACTURE OF STERILE MEDICINAL PRODUCTS (中英文对照)(a) These are average values. (一)这些都是平均值。
(b) Individual settle plates may be exposed for less than 4 hours. (二)单个沉降皿放置的时间可以少于4小时。
20. Appropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If these limits are exceeded operating procedures should prescribe corrective action。
对尘埃粒子和微生物的监控结果,要设置适当的警戒限度和行动限度。
当超出这些限度时,操作规程应说明需要采取的措施。
Isolator technology 隔离技术21. The utilisation of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbiological contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for the respective zones can be realised. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from a single door to double door designs to fully sealed systems incorporating sterilization mechanisms. 在生产区采用人员方面的隔离技术,在无菌产品的生产中,会显著降低周围环境微生物污染的风险。
制药验证文件-洁净空压机验证方案(英文版)
Qualification Protocol for New Air Compressor (COMP04)1. Short Description of Project / Facility / System1.1 Project DescriptionAs part of the “Extension of Production Facility, ChangPing” Project (EPCP, No. CNPHCP200502), a new Air Compressor COMP04 will be installed in the existing utilities area for the complementary production of compressed air.For general information, reference is made to:EPCP_11_06_INFRA_URS (current version)●INFRA URS,EPCP_01_00_HLD_URS (current version)●Project URS,EPCP_01_00_HLD_QMP (current version)●Project Qualification Master Plan,EPCP_01_00_HLD_QNA (current version)●Qualification Need Assessment,●Functional Risk Assessment EPCP_11_03_CA_FRA_2.0EPCP - CR 0238●Change request (new compressor)1.2 Functional Description for the ZT compressor with IMD dryer.NB. For the complete functionality of the CA system refer to the functional specification EPCP_11_03_CA_FS in its current version.Air drawn in through air filter (AF) and the open inlet valve of the unloader assembly (UA) is compressed in the low-pressure compressor element (El) and discharged to the intercooler (Ci).The cooled air is further compressed in the high-pressure compressor element (Eh) and discharged through the pulsation damper (AS) and the after cooler (Ca).A check valve (CV) is provided downstream of the pulsation damper (AS).When the compressor switches to unload operation, the air trapped in the pulsation damper and the high-pressure element is blown off via the blow-off silencer (US).The check valve (CV) prevents compressed air downstream the check valve to be blown off.Flow diagramAF Air filter (1) IMD bypass valve M4 Gear motor, IMD AS Pulsation damper (2) IMD air inlet valve EWD ElectronicCV Check valve drain, inlet airUS Blow-off silencer (3) DemisterCa After cooler with integrated drain (4) Nozzle Car Regeneration air cooler, IMD collector (5) IMD outlet valve FN Fan, regeneration air IS Inlet silencer cooler to air outlet valve (customer’sUA Unloader assembly installation)EWDa Electronic drain, after cooler (6) Rotor, IMDOP Oil pump (7) Regulating valve regeneration airCi Intercooler with integrated drain collectorGC Oil sump (gear casing)EWDi Electronic drain, intercoolerCo Oil coolerEh High-pressure compressor elementOF Oil filterEl Low-pressure compressor elementFN1 Cooling fan (ZT)1.3 Main emphasis on quality critical issues1.3.1 GMP Risk AssessmentThe air compressor installation will be in compliance with the valid Project Qualification Master Plan, Doc. No. EPCP_01_00_HLD_QMP, EPCP_11_03_CA_FRA in their current version.1.3.2 Critical measurement instrumentsInstruments for : Operating pressure, Dew point and Temperature.1.3.3 Critical items/functionsSpecification for construction material of operational parts.Air drying process.1.3.4 Qualification strategyThe air compressor qualification is covered by the following documents:URS,GMP and Functional Risk AssessmentQualification Protocol (QP)DQ, IQ & OQQualification Report (QR).Notes:1. No separate CSV Qualification Protocol and Qualification Report are needed since itis a Class 4 system.2. A 21CFR Part 11 Risk Assessment is not requested because the control system is notable to store any data.3. The air compressor and its auxiliaries will be commissioned with the support of aVendor Engineer.5. T he Qualification (DQ/IQ/OQ) will be prepared by BNP’s own Engineers, based onthis QP. The Qualification Documentation will be prepared by Luwa.6. The calibration during IQ will be executed by the vendor technician supervised byBNP R&M engineers.7. The qualification strategy and tests scope will be based on the qualification of theexisting air compressor (same supplier, same type). No new GMP and Risk Assessment will be prepared.2. Steps covered in this ProtocolFor the Qualification of the air compressor, the present QP will be followed. The qualification documents for the air compressor will be created (DL and DQ, IQ, OQ) and will be filed with this qualification.NB: This Qualification plan does not include interfacing utilities. For information about the qualification of the CA system, see EPCP_11_03_CA_QP in its current version.Design Qualification (DQ): yes: no: NA: Commissioning (GEP) 1): yes: no: NA: Installations Qualification (IQ): yes: no: NA: Operational Qualification (OQ): yes: no: NA: Operational Qualification (PQ) 2): yes: no: NA:1) Only FAT and correct installation before IQ (SAT)2) PQ will be done by checking the Pressure and microbial test at the exhaust of the new air compressor. No water content testing will be made as the dryness and oil free status is certified by the manufacturer.Copies of the certificates will be filed in the qualification binder.3. Documentation3.1 Qualification Documents List (GPE_FRM_511_0071)Refer to “Qualification Document List for the air com pressor, EPCP_11_03_CA_COMP04_DL” in its current version.3.2 Project Specific SOP’sNo project specific SOPs for the commissioning execution of this new air compressor.3.3 Administration of DocumentsThe Documents are filed according to “Document Management Syst em:Doc. No EPCP_01_00_HLD_DMS” in its current version.4. Basics4.1 Basic SOP’sGPE_SOP_508_0484: Concept for Commissioning and QualificationEPCP-SOP-001: CommissioningGPE_SOP_511_0042: Specification, Execution and Deviation Resolution of TestsGPE_SOP_511_0030 Handling of Changes (Engineering Projects)4.2 Project Specific AgreementsTwo types of training activities will be conducted one training for qualification execution and an other training for operation and maintenance.Qualification execution training is mandatory for all persons taking part in the qualification work. The training will be conducted by Luwa, and each test person shall complete the training before the empowerment to execute qualification and commissioning activities. Operation and maintenance training will be conducted by the EPCP or the vendor. Luwa operators, engineers or technicians should complete the training based on the functional requirements.Luwa Persoamal Training Record (FRM_000037) and Training Record (FRM_000039) will be used to document the training.5. Qualification Activities (Action Plan)5.1 Project Time ScheduleRefer to project time schedule in its current version.5.2 Qualification Activities (included in Project Time Schedule)All qualification activities are summarized in “Section 1.3 Main emphasis on quality critical issues”, “Section 3.1 Qualification Documents List”.6. Organization / Responsibility6.1 Qualification OrganizationRefer to “Qualification Master Plan, EPCP_01_00_HLD_QMP” for responsibilities matrix. 6.2 Project OrganizationThe organization is within the current EPCP organization chart in PPM.7. Attachments to ProtocolAttachment 1 Qualification Document List for air new compressor,EPCP_11_03_CA_COMP04_DL in its current version.。
制药工程GMP(清洁验证)
总残留量最大允许界限 X棉签取样面积 X 取样效率 设备内总表面积 X 棉签使用溶剂量
取样及检验方法
微生物检验
棉签取样检验 最终冲洗水取样检验
总有机碳(TOC)测试
– 测量擦洗或冲洗后的水样中总有机碳的量
淋洗法取样
该方法是用已知溶剂量来淋洗设备表面。 一般淋洗样品适用于可以最后淋洗的密闭设 备;如果可能应对整个设备体系进行淋洗。
淋洗法取样
优势 适合在线检测 出结果快 取样简单 适用于大面积和难以达 到的位置取样 仅表面取样 多种药物残渣可以溶出 可以加大溶剂/冲洗水 的量,增加药物残渣的 溶出 劣势 不能直接在表面取样 残渣的溶解性取决于溶 剂的性能 检验量大 冲洗溶剂的用量大 冲洗水样可能要求浓缩 或预先浸出 不能保证相同性质的溶 出物
分析方法选择 和验证
当可接受标准量很小时, 样品处理方法: <1> 对照品溶液加入法 <2> 增加取样面积或取样量 <3> 浓缩法
活性物质残留限度的确定
与生物活性有关的限度
–
最大可允许进入后续产品中的残留物总量: 产品活性强度(最小值)X产品批量(最小值) 日服用剂量(最大值)
产品活性强度
良好的清洁结果的重要性
降低交叉污染的风险 使得产品受污染报废的可能性最小 患者的负面效应可能性最小 降低产品投诉的发生率 降低卫生部门或其他机构检查不合格的风险 延长设备的使用寿命
设备清洁的类型
手工清洗
*
由操作人员用擦洗或用高压软管等进行的清洗
自动清洗
*
由自动控制系统进行洗刷直至干燥的清洗
洁净空调确认计划(英文版)
Qualification Plan for AHU19 SystemDistribution list:AuthorLuwa Qualification Coordinator (Original)Reason for Change1. Short Description of Project / Facility / System1.1 Project DescriptionThis Qualification Plan defines the qualification activities, procedures, andresponsibilities for the secondary packing HVAC System AHU19, as part of theoverall qualification effort for the “Extension of Production Facility ChangPing” ofBeijing Luwa Pharma. Ltd., ChangPing Plant.For general information, see the following documents in its current version:Project URS Doc. No. EPCP_01_00_HLD_ URSHVAC URS Doc. No. EPCP_11_08_HVAC_URSQualification Master Plan (QMP) Doc. No. EPCP_01_00_HLD_QMPQualification Need Assessment (QNA) Doc. No. EPCP_01_00_HLD_QNA 1.2 Functional DescriptionThe secondary packing area is classified as a Luwa Zone 3 area, which comprise the following rooms:A-407 Packaging AreaA-409 Packaging Waste Air LockAHU19 is supplied with preconditioned air from PCU1. Further air treatments within the AHU19 are in the following way:∙Cooling coil (AHU)∙Heating coil (AHU)∙Fan (AHU)∙Silencer (AHU)∙Filter F9 (AHU)For the return air from AHU19 will be treated in the following way:∙Filter G4 (filter in the room)∙Fan (AHU)Then back to AHU19 and PCU1 as recirculation air.For detail information, refer to AHU19 PID (Doc. No. EPCP_11_08_AHU19_PID) and Function Specification (Doc. No. EPCP_11_08_AHU19_FS) in its currentsversion.1.3 Main Emphasis on Quality Critical Issues1.3.1 GMP Risk AssessmentIn the URS for HVAC System (Doc. No. EPCP_11_08_HVAC_URS), eachrequirement is assessed for GMP Relevance.A “GMP and Functional Risk Assessment for AHU systems” (Doc. No.EPCP_11_08_HVAC_RA) defines the critical qualification activities, which is thebasis for this qualification plan.For general information, see the overall Project “GMP Risk Assessment” (Doc. No.EPCP_11_00_HLD_GMPRA).1.3.2 Critical Measurement InstrumentsA list of instruments will be prepared for DQ and approved before IQ execution. Allcritical sensors which shall be calibrated periodically will be defined in the calibration list according to the sensor risk assessment.2 Steps Covered in this Qualification PlanDesign Qualification (DQ) Yes: No: N/A:Installations Qualification (IQ) Yes: No: N/A:Operational Qualification (OQ) Yes: No: N/A:Performance Qualification (PQ) Yes: No: N/A:3 Documentation3.1 Qualification Documents ListThe “Qualification Document List” (Doc. No. EPCP_11_08_AHU19_DL) outlines the documents to be prepared, assigned to the different Qualification Phases.The list will be updated in each qualification phase and finally completed and attached to the qualification report.3.2 Administration of DocumentsThe Qualification Coordinator from MAM is responsible for the entire documentation until handover to the Luwa.Documents are filed according to “Project Documentation Management System” (Doc.No. EPCP_01_00_HLD_DMS in its current version).4 Basics4.1 Basic SOP’sGPE_SOP_508_0484: Concept for Commissioning and Qualification (SOP-0019069) EPCP_PSOP_001: Commissioning for Facility and EquipmentGPE_SOP_511_0042: Specification, Execution and Deviation Resolution of Tests4.2 Project Specific Agreements4.2.1 Additional SOP’s from Luwa GPEGPE_SOP_511_0030: Handling of Changes in Engineering Projects4.2.2 TrainingTwo types of training activities will be conducted - training for qualification execution and training for operation and maintenance.Qualification execution training is mandatory for all persons taking part in thequalification work. The training will be conducted by MAM, and each test personshall complete the training before any test activities such as DQ, IQ, OQ and PQ canstart.Operation and maintenance training will be conducted by relevant supplier. The Luwa operators and maintenance technicians shall complete the training before PQ testactivities. Luwa PersoMAMl Training Record (FRM_000037) and Training Record(FRM_000039) shall be used to document the training.4.2.3 Specific indication for the qualification AHU19In order to ensure the generally project schedule, it was necessary to create severalGEP related documents earlier than this qualification plan. (e.g. duct leakage test,hydraulic test)5 Qualification Activities (Action Plan)5.1 Project Time ScheduleSee Project Time Schedule in its current version.5.2 Qualification Rules and Sequence of Activities5.2.1 General Qualification ProcessThe qualification process will be based on the URS, Risk Assessment andQualification Plan, DQ/IQ/OQ/PQ test specifications. The test results will besummarized in the Qualification Report.5.2.2 DQDQ documents that the design of HVAC system fulfills the URS and GMP RiskAssessment.The Design is qualified when all design documents are marked with a signed DQstamp or approved with approval signatures.DQ confirms the details of the technical design.Scope of DQ:All relevant design documents, are defined in the Qualification Documents List, shall be qualified and filed in the Test Binder.The DQ is completed when the DQ Release Form is signed by all relevant approvers.When DQ is completed the formal Project Change Control Procedure will be in effect,see “Project Documentation Management System” (Doc. No.EPCP_01_00_HLD_DMS).5.2.3 Installation Qualification (IQ)IQ contains a series of tests which documents that the system has been appropriatelyinstalled on Site.IQ pre-requisites:∙The DQ release form have to be signed by all relevant approvers∙All documents on the Qualification Documents List must be available and filed in the Test Binder∙All IQ Test Specifications have to be approved by Luwa before test activities can begin∙All test instruments shall be calibrated and have calibration certificates IQ tests are listed in the IQ Test Specification.All deviations found during IQ execution will be handled according to the deviationmanagement concept described in section 5.2.6.The IQ is complete when the IQ Release Form is signed by all relevant approvers.5.2.4 Operation Qualification (OQ)OQ contains a series of tests which documents that the system’s function performs asdescribed in the Functional Specification.OQ pre-requisites:∙The IQ release form has to be signed by all relevant approvers.∙All documents on the Qualification Documents List must be available and filed in the Test Binder∙All OQ Test Specifications have to be approved by Luwa before test activities can begin∙All test instruments shall be calibrated and have calibration certificates∙The system is commissioned and the release form signed by relevant approvers.The OQ will be executed in two phases: HVAC equipment and HVAC automationsystem.OQ tests are listed in the OQ Test Specification.All deviations found during OQ execution will be handled according to the deviationmanagement concept described in section 5.2.6.The OQ is complete when the OQ Release Form is signed by all relevant approvers.5.2.5 Performance Qualification (PQ)PQ contains a series of tests which documents that the HVAC system and thecoMAM cted rooms’ performance are in compliance with the Zoning Diagram and theURS.PQ pre-requisites:∙The OQ release form have to be signed by all relevant approvers∙All documents on the Qualification Document List must be available and filed in the Test Binder∙All PQ Test Specifications have to be approved by Luwa before test activities can begin∙All test instruments shall be calibrated and have calibration certificates∙The HVAC system and the coMAMcted rooms must be cleaned and checked according to approved cleaning SOPs.The PQ will be executed in two phases: PQ at rest and PQ in operation.5.2.5.1 PQ at restPQ at rest comprises the tests in the PQ Test Specification.All deviatio ns found during PQ “at rest” execution will be handled according to thedeviation handling SOP-000002.The PQ at rest is complete when the PQ at rest Release Form is signed by all relevant approvers.5.2.5.2 PQ in operationPQ in operation comprises the tests in the PQ Test Specification.PQ in operation shall be executed under normal operation conditions.All deviations found during PQ “in operation” execution will be handled accordingto the deviation handling SOP-000002.The PQ in operation is complete when the PQ in operation Release Form is signedby all relevant approvers.5.2.6 Qualification Deficiency / Deviation5.2.6.1 Deficiency / Deviation ListDeficiency / Deviation List is used in DQ/IQ/OQ phase.The Deficiency / Deviation List will be used to track open items which arise duringthe course of each phase.For Deviation in PQ “at rest and in operation” see 5.2.5.1 and 5.2.5.25.2.6.2 Deviation FormDeviation form is used in the IQ/OQ phase.A consecutive numbers starting at AHU19_xQ_DEV001.The proposal for corrective action must be proposed by test engineer and approvedby BNP discipline engineer.The implementation and re-inspection of corrective action must be finally approvedby the BNP discipline engineer.5.2.7 Release FormThe “Release Form” (Basic Doc. No.: EPCP_511_0067) for IQ/OQ/PQ/Productionshall be used to release each qualification phase. Without an approved release from the prior phase the next qualification phase can not begin.A copy of the test “Deficiency list” shall be attached to the “Release Form” forrespective qualification phase.5.2.8 Qualification ReportWhen the PQ “at rest” is completed, the Qualification Report (QR) will be prepared,and it will summarize all qualification activities and results from DQ, IQ, OQ and PQ “at rest“.The Qualification Report verifies that all qualification activities described in theQualification Plan, except PQ “in operation“, have been successfully performed andfulfills the accept criteria. Further more, that all observed deviations have beenhandled and closed successfully.A fter the PQ “in operation“, a Final Report will be prepared, which summarizes allactivities and results from the PQ in operation phase.The approved QR and Final Report combined confirm that the qualification iscompleted and the system is fully qualified.6 Organization / Responsibility6.1 Qualification OrganizationPeople from Luwa, MAM, Sauter and Xinxing will participate in the qualification of the AHU19 system.6.2 ResponsibilityThe responsibility of the MAM Quality Engineer:∙Prepare the QP and collect corresponding documents according to the agreed responsibility matrix Doc. No. EPCP_08_00_HVAC_RM in its current version The responsibility of the MAM Project Engineer:∙Secure correct systems description and that all technical issues are correct and meet the technical requirements∙Ensure that scope and contents are adequateThe responsibility of the MAM QA:∙Secure compliance with the EPCP_HLD and cGMP∙Secure correct referencesThe BNP responsibility:∙See QMP Responsibilities Matrix Qualification Master Plan (QMP) in its current versionDoc. No. EPCP_01_00_HLD_QMPIn general, all the responsibilities of Luwa, MAM, Sauter, Xinxing are defined in theHVAC Responsibility Matrix Doc. No. EPCP_08_00_HVAC_RM in its current version.7 AbbreviationAHU Air Handling UnitBNP Beijing Luwa PharmaDMS Document Management SystemEPCP Extension Project ChangPingFRM FormGPE Luwa Global Pharma EngineeringGMP Good Manufacturing PracticeHLD High Level DocumentHVAC Heating, Ventilation and Air ConditioningIQ Installation QualificationMAM MAM (Tianjin) Co., Ltd.OQ Operation QualificationPQ Performance QualificationQA Quality AssuranceQP Qualification PlanQMP Qualification Master PlanQNA Qualification Need AssessmentQR Qualification ReportTS Test SpecificationSOP Standard Operating ProcedureURS User Requirement Specification8 AMAMxAMAMx 1 Qualification Document List (Doc No. EPCP_11_08_AHU19_DL)。
GMP中英文对照
GMP相关的英文缩写1. AQAI(Automated Quality Assurance Inspection Equipment):在线自动质量保证检查设备.2. API(Active Pharmaceutical Ingredient):活性药物物质,即原料药.3. ANDA (Abbreviated New Drug Application):简化新药申请.4. ADR(Adverse Drug Reaction):不良反应.5. BSE(Bovine Spongiform Encephalopathy):疯牛病.6. BPCS(Business Planning and Control System):业务计划及控制系统.7. BIA(Business impact assessment): 商业影响评估.8. cGMP(current Good Manufacturing Practice):现行药品生产质量管理规范.9. CCCD(China Certification Committee for Drugs):中国药品认证委员会.10. CIP(Cleaning In Place):在线清洁. 11. CV(Concurrent Validation):同步验证.12. CDER( Center for Drug Evaluation and Research): 药品研究与评价中心.13. COA(Certificate Of Analysis):分析报告单.14. CFR(Code of Federal Regulation):(美国)联邦法规.15. CDC(Centers for Disease Control and Prevention):疾病预防控制中心.16. COS / CEP( Certificate of Suitability for European Pharmacopeia ):欧洲药典适用性证书.17. CCD (Certification Committee for Drugs):药品认证管理中心. 18. CPMP(Committee for Proprietary Medicinal Products): 欧洲专利药品委员会.19. CTD(Common Technical Document):通用技术文件.20. CDC( Centers for Disease Control and Prevention): 疾病预防控制中心.21. GMP(Good Manufacturing Practice):药品生产质量管理规范. 22. ICH(International Conference on Harmonization of Technical Requ irements for Registration of Pharmaceuticals for Human Use):人用药品注册技术要求国际协调会. 23. EU(European Union):欧洲联盟.24. EFPIA(European Federation of Pharmaceutical Industries Associations ):欧洲制药工业协会联合会.25. MHW(Ministry of Health and Welfare,Japan):日本厚生省. 26. JPMA(Japan Pharmaceutical Manufacturers Association):日本制药工业协会.27. FDA(US Food and Drug Adminiistration):美国食品与药品管理局.28. PRMA(Pharmaceutical Research and Manufacturers of America):美国药物研究和生产联合会.29. WHO(World Health Organization):世界卫生组织.30. IFPMA(International Federation of Pharmaceutical Manufacturers As sociations):国际制药工业协会联合会.31. TQC(Total Quality Control),TQM(Total Quality Management): 全面质量管理.32. PDCA(Plan,Do,Check,Action):计划,执行,检查,处理.33. QA(Quality Assurance):质量保证.34. QC (Quality Control):质量控制.35. QS(Quality System):质量体系.36. QM(Quality Management): 质量管理.37. SOP(Standard Operating Procedure): 标准操作规程.38. SMP(Standard Management Procedure):标准管理程序.39. SOR(Standard Operating Record): 标准操作记录.40. GEP(Good Engineering Practice):工程设计规范.41. HVAC(Heating Ventilation and Air Conditioning):空调净化系统.42. DQ(Design Qualification):设计确认.43. IQ(Installation Qualification):安装确认.44. OQ(Operational Qualification):运行确认.45. PQ(Performance Qualification):性能确认.46. OOS(Out-Of-Specification):检验不合格;超标.47. PFDS(Process Flow Diagrams):工艺流程图.48. MRA(cMutual Reognition Agreements): 现场检查多边认同协议.49. DMF( Drug Master File):药物主文件.50. EDMF(European Drug Master File)欧盟药物主文件.51. EDQM(European Directorate for Quality Medicines): 欧洲药品质量管理局.52. ORA(Office of Regulatory Affairs):药政事务办公室.53. GGPs( Good Guidance Practices): 优良指南规范.54. MOA(Method Of Analysis):分析方法.55. VMP(Validation Master Plan):验证主计划.56. VP(Validation Protocol):验证方案.57. MSDS(Material Safety Data Sheet):物料安全技术说明书.58. NDA (New Drug Application):新药申请.59. OTC(Over-the-counter):非处方.60. INN(International Nonproprietary Name):国际非专有名称.61. USP(the united state pharmacopeia): 美国药典.62. NF(National Formulary):(美国)国家药品集.63. GAP(Good Agricultural Practice):中药材种植管理规范.64. GCP(Good Clinical Practice):药物临床试验质量管理规范.65. GLP(Good Laboratory Practice):药物实验室管理规范.66. GSP(Good Supply Practice):药品经营质量管理规范.67. GUP(Good Use Practice):药品使用质量管理规范.68. SM(Starting Material):起始物料.69. PMF(Plant Master File); SMF(Site Master File):工厂主文件.70. EDL(List of Essential Drugs ) : 基本药物目录.71. PI(Package Insert):说明书.72. PCT( Patent Cooperation Treaty): 专利合作条约.73. PPAC(Patent Protection Association of China):中国专利保护协会.74. PIC( Person In Charge) :负责人.75. PDS(Pharmaceutical Development Services): 整体新药研发机构.76. SPC(Summary of Product Characteristics):产品特性摘要.。
制药工程GMP(清洁验证)
100 mg
微生物取样
对难以接触的表面用棉签取样
对平直表面用RODAC板
微生物取样应在化学取样前进行
清洁验证检验方法
检验方法对于分析物是特定的
检验方法必须经过验证
– 专属性 – 灵敏度 – 精密度 – 线性范围
– 回收率(取样和检验)
分析方法选 择和验证
常用的分析 方法:
分析方法选 择和验证
良好的清洁结果的重要性
降低交叉污染的风险 使得产品受污染报废的可能性最小 患者的负面效应可能性最小 降低产品投诉的发生率 降低卫生部门或其他机构检查不合格的风险 延长设备的使用寿命
设备清洁的类型
手工清洗
*
由操作人员用擦洗或用高压软管等进行的清洗
自动清洗
*
由自动控制系统进行洗刷直至干燥的清洗
清
洗
验
证
第八十四条 应当按照详细规定的操作规程清洁 生产设备。 生产设备清洁的操作规程应当规定具体而完 整的清洁方法、清洁用设备或工具、清洁剂的名 称和配制方法、去除前一批次标识的方法、保护 已清洁设备在使用前免受污染的方法、已清洁设 备最长的保存时限、使用前检查设备清洁状况的 方法,使操作者能以可重现的、有效的方式对各 类设备进行清洁。
清洁规程要点
拆卸(程度)要求 每一步的清洗要求 – 浸泡/预冲洗/清洗/喷淋时间、温度要求 – 清洗剂名称/浓度/数量/配制方法 – 清洁工具要求 消毒/灭菌,方法及相关参数 干燥方法 清洁后检查要求
清洁规程要点
生产结束至开始清洁的最长时间要求 设备连续使用的最长时间 清洁后设备的储存和条件 已清洁设备的最长存放时间 设备的清洁状况标识 过清洁有效期设备的处理 设备使用前的检查 装配要求
某公司已过新版GMP认证洁净厂房验证模版(中英文)
CleanRoomInstallationQualificationProtocol干净室安装确认方案SystemNo.系统编号:CLR-01Index名目1. Purpose目的本安装确认方案的目的是测试、检查和干净室是按照相应设计要求和需求商的建议进行安装的。
安装确认的测试和检查的结果将按照该验证方案进行记录。
安装确认将确定直截了当妨碍系统的要害部件被正确地安装,并符合设计文件需求;确定支持文件、质量文件在现场。
测试和检查的结果将按照该验证方案进行记录。
2. Scope范围本方案确定了***********公司口服固体工程车间的干净室〔位号:***********〕的安装确认。
3. Responsibility职责4. RegulationandGuidance法规和指南(SFDA)GMP2021版中国药典2021版现行版ISPE指南5“调试和确认〞干净厂房设计标准GB13554-92 5. Abbreviations缩略语6. SystemDescription系统描述口服固体制剂的干净室包括以下级不D级区非要害生产步骤的干净区对产品无妨碍的房间无需验证。
7. GoodDocumentationPractice文件治理标准记录用笔:- 使用不消退的墨水笔和记号笔,推举使用蓝色笔记录签名:- 被授权的人员才能签署文件- 应签全名,除非文件另有规定- 签名应该是可识不的- 签名应始终一致填写栏目:- 所有栏目必须填写- 填写内容与上面栏目相同应重新填写- 假设有单个栏目不需要填进内容,那么在空白处填写英文字母“不适用〞的简写“N/A〞,以表示无此项内容。
- 填写记录时,假设有多个栏目不需要填进内容,应用歪线划掉,歪线上方填写“N/A,下方签名和注明日期。
签名及日期应尽量沿歪线同侧填写。
文件刚完成,马上更改的在错误处划线,填进正确的,签名和注明更改日期,确保原先信息仍清楚可识不如:2010年01月01日签字,日期事后更改的,除非马上更改的要求外,还应注明更改的缘故,检查和注释可能的妨碍。
ICH q7a (中英文对照)
Q7a(中英文对照)FDA原料药GMP指南Table of Contents 目录1. INTRODUCTION 1. 简介1.1 Objective 1.1目的1.2 Regulatory Applicability 1.2法规的适用性1.3 Scope 1.3范围2. QUALITY MANAGEMENT 2.质量管理2.1 Principles 2.1总则2.2 Responsibilities of the Quality Unit(s) 2.2质量部门的责任2.3 Responsibility for Production Activities 2.3生产作业的职责2.4 Internal Audits (Self Inspection) 2.4内部审计(自检)2.5 Product Quality Review 2.5产品质量审核3. PERSONNEL 3. 人员3.1 Personnel Qualifications 3.人员的资质3.2 Personnel Hygiene 3.2 人员卫生3.3 Consultants 3.3 顾问4. BUILDINGS AND FACILITIES 4. 建筑和设施4.1 Design and Construction 4.1 设计和结构4.2 Utilities 4.2 公用设施4.3 Water 4.3 水4.4 Containment 4.4 限制4.5 Lighting 4.5 照明4.6 Sewage and Refuse 4.6 排污和垃圾4.7 Sanitation and Maintenance 4.7 卫生和保养5. PROCESS EQUIPMENT 5. 工艺设备5.1 Design and Construction 5.1 设计和结构5.2 Equipment Maintenance and Cleaning 5.2 设备保养和清洁5.3 Calibration 5.3 校验5.4 Computerized Systems 5.4 计算机控制系统6. DOCUMENTATION AND RECORDS 6. 文件和记录6.1 Documentation System and 6.1 文件系统和质量标准Specifications6.2 Equipment cleaning and Use Record 6.2 设备的清洁和使用记录6.3 Records of Raw Materials, Intermediates, API Labeling and Packaging Materials 6.3 原料、中间体、原料药的标签和包装材料的记录6.4 Master Production Instructions (MasterProduction and Control Records)6.4 生产工艺规程(主生产和控制记录)6.5 Batch Production Records (BatchProduction and Control Records)6.5 批生产记录(批生产和控制记录)6.6 Laboratory Control Records 6.6 实验室控制记录6.7 Batch Production Record Review 6.7批生产记录审核7. MATERIALS MANAGEMENT 7. 物料管理7.1 General Controls 7.1 控制通则7.2 Receipt and Quarantine 7.2接收和待验7.3 Sampling and Testing of IncomingProduction Materials7.3 进厂物料的取样与测试7.4 Storage 7.4储存7.5 Re-evaluation 7.5复验8. PRODUCTION AND IN-PROCESSCONTROLS8. 生产和过程控制8.1 Production Operations 8.1 生产操作8.2 Time Limits 8.2 时限8.3 In-process Sampling and Controls 8.3 工序取样和控制8.4 Blending Batches of Intermediates orAPIs8.4 中间体或原料药的混批8.5 Contamination Control 8.5 污染控制9. PACKAGING AND IDENTIFICATIONLABELING OF APIs ANDINTERMEDIATES9. 原料药和中间体的包装和贴签9.1 General 9.1 总则9.2 Packaging Materials 9.2 包装材料9.3 Label Issuance and Control 9.3 标签发放与控制9.4 Packaging and Labeling Operations 9.4 包装和贴签操作10. STORAGE AND DISTRIBUTION 10.储存和分发10.1 Warehousing Procedures 10.1 入库程序10.2 Distribution Procedures 10.2 分发程序11. LABORATORY CONTROLS 11.实验室控制11.1 General Controls 11.1 控制通则11.2 Testing of Intermediates and APIs 11.2 中间体和原料药的测试11.3 Validation of Analytical Procedures 11.3 分析方法的验证11.4 Certificates of Analysis 11.4 分析报告单11.5 Stability Monitoring of APIs 11.5 原料药的稳定性监测11.6 Expiry and Retest Dating 11.6 有效期和复验期11.7 Reserve/Retention Samples 11.7 留样12. V ALIDATION 12.验证12.1 Validation Policy 12.1 验证方针12.2 Validation Documentation 12.2 验证文件12.3 Qualification 12.3 确认12.4 Approaches to Process Validation 12.4 工艺验证的方法12.5 Process Validation Program 12.5 工艺验证的程序12.6 Periodic Review of Validated Systems 12.6验证系统的定期审核12.7 Cleaning Validation 12.7 清洗验证12.8 Validation of Analytical Methods 12.8 分析方法的验证13. CHANGE CONTROL 13.变更的控制14. REJECTION AND RE-USE OFMATERIALS14.拒收和物料的再利用14.1 Rejection 14.1 拒收14.2 Reprocessing 14.2 返工14.3 Reworking 14.3 重新加工14.4 Recovery of Materials and Solvents 14.4 物料与溶剂的回收14.5 Returns 14.5 退货15. COMPLAINTS AND RECALLS 15.投诉与召回16. CONTRACT MANUFACTURERS(INCLUDING LABORATORIES)16.协议生产商(包括实验室)17. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS 17.代理商、经纪人、贸易商、经销商、重新包装者和重新贴签者17.1 Applicability 17.1适用性17.2 Traceability of Distributed APIs andIntermediates17.2已分发的原料药和中间体的可追溯性17.3 Quality Management 17.3质量管理17.4 Repackaging, Relabeling, and Holding of APIs and Intermediates 17.4原料药和中间体的重新包装、重新贴签和待检17.5 Stability 17.5稳定性17.6 Transfer of Information 17.6 信息的传达17.7 Handling of Complaints and Recalls 17.7 投诉和召回的处理17.8 Handling of Returns 17.8 退货的处理18. Specific Guidance for APIs Manufactured by Cell Culture/Fermentation 18. 用细胞繁殖/发酵生产的原料药的特殊指南18.1 General 18.1 总则18.2 Cell Bank Maintenance and RecordKeeping18.2细胞库的维护和记录的保存18.3 Cell Culture/Fermentation 18.3细胞繁殖/发酵18.4 Harvesting, Isolation and Purification 18.4收取、分离和精制18.5 Viral Removal/Inactivation steps 18.5 病毒的去除/灭活步骤19.APIs for Use in Clinical Trials 19.用于临床研究的原料药19.1 General 19.1 总则19.2 Quality 19.2 质量19.3 Equipment and Facilities 19.3 设备和设施19.4 Control of Raw Materials 19.4 原料的控制19.5 Production 19.5 生产19.6 Validation 19.6 验证19.7 Changes 19.7 变更19.8 Laboratory Controls 19.8 实验室控制19.9 Documentation 19.9 文件20. Glossary 20. 术语Q7a GMP Guidance for APIs Q7a原料药的GMP指南1. INTRODUCTION 1. 简介1.1 Objective 1.1目的This document is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the quality and purity characteristics that they purport, or are represented, to possess. 本文件旨在为在合适的质量管理体系下制造活性药用成分(以下称原料药)提供有关优良药品生产管理规范(GMP)提供指南。
PIC S VMP 验证主计划(中英文对照)
OPERATIONAL QUALIFICATION STERILE PROCESS VALIDATIONCLEANING VALIDATION (1/25)1. DOCUMENT HISTORYAdoption by PIC/S Committee 10 - 11 December 1998Entry into force of version PR 1/99-1 01 March 1999Entry into force of version PI 006-1 01 September 20012. INTRODUCTIONThe basic principles and application of qualification and validation are describedin Annex 15 to the PIC/S and EU Guide to GMP. This document comprises individual Recommendations on four topics relating to Equipment Qualification and Process Validation in pharmaceutical manufacture, as follows:Ø Validation Master PlanØ Installation and Operational QualificationØ Non-Sterile Process ValidationØ Cleaning ValidationThe four Recommendations comprising this document define general principles pertaining to each of the topics.2. 导言PIC/S和EU GMP指导原则的附录15中对确认(Qualification)和验证(Validation)的基本原则及应用进行了阐述。
洁净词汇中英文对照
GMP英语PIC/S的全称为:Pharmaceutical InspectionConvention/Pharmaceutical Inspection Cooperation Scheme, PIC/S(制药检查草案), 药品检查协会(PIC/S) ,也有人称PIC/S为医药审查会议/合作计划(PIC/S)PIC的权威翻译:药品生产检查相互承认公约API(Active Pharmaceutical Ingredient) 原料药又称:活性药物组分Air Lock 气闸Authorized Person 授权人Batch/Lot 批次Batch Number/Lot-Number 批号;Batch Numbering System 批次编码系统;Batch Records 批记录;Bulk Product 待包装品;Calibration 校正;Clean area洁净区;Consignment(Delivery)托销药品。
FDA(FOOD AND DRUG ADMINISTRATION):(美国)食品药品管理局IND(INVESTIGATIONAL NEW DRUG):临床研究申请(指申报阶段,相对于NDA而言);研究中的新药(指新药开发阶段,相对于新药而言,即临床前研究结束)NDA(NEW DRUG APPLICATION):新药申请ANDA(ABBREVIATED NEW DRUG APPLICATION):简化新药申请TREATMENT IND:研究中的新药用于治疗ABBREVIATED(NEW)DRUG:简化申请的新药DMF(DRUG MASTER FILE):药物主文件(持有者为谨慎起见而准备的保密资料,可以包括一个或多个人用药物在制备、加工、包装和贮存过程中所涉及的设备、生产过程或物品。
只有在DMF持有者或授权代表以授权书的形式授权给FDA,FDA在审查IND、NDA、ANDA时才能参考其内容)HOLDER:DMF持有者CFR(CODE OF FEDERAL REGULATION):(美国)联邦法规PANEL:专家小组BATCH PRODUCTION:批量生产;分批生产BATCH PRODUCTION RECORDS:生产批号记录POST-OR PRE- MARKET SURVEILLANCE:销售前或销售后监督INFORMED CONSENT:知情同意(患者对治疗或受试者对医疗试验了解后表示同意接受治疗或试验)PREscriptION DRUG:处方药OTC DRUG(OVER—THE—COUNTER DRUG):非处方药GMP文件常见缩写ABPI Association of the British Pharmaceutical Industry ADR Adverse Drug Reaction AE Adverse EventAIM Active Ingredient ManufacturerANDA Abbreviated New Drug ApplicationANOVA Analysis of VarianceASM: Active Substance ManufacturerATC Anatomical Therapeutic ChemicalATX Animal Test Exemption CertificateBAN British Approved NameBIRA British Institute of Regulatory AffairsBNF British National FormularyBP British PharmacopoeiaC of A Certificate of AnalysisC of S Certificate of SuitabilityCENTRE FOR DRUG EVALUATION (CDE)Centre for Pharmaceutical Administration (CPA)CMS Concerned Member State CMS每个成员国COS Certificate of SuitabilityCPMP Committee for Proprietary Medicinal Products CRA Clinical Research AssociateCRF Case Report FormCRO Contract Research OrganizationCTA Clinical Trial ApplicationCTC Clinical Trial CertificateCTD Common Technical documentCTX Clinical Trials ExemptionDDD Defined Daily DoseDGC Daily Global ComparisonDIA Drug Information AssociationDMF Drug Master FileDrug Registration Branch (DR, Product Evaluation & Registration Division, CPAEDQM (European Directorate for the Quality of Medicines) 欧洲联盟药品质量指导委员会EEA 欧洲经济地区EGMA European Generics Medicine AssociationELA Established License ApplicationEMEA European Medicines Evaluation AgencyEMEA (European Agency for the Evaluation of Medicinal Products)欧洲联盟药品评价机构EP European PharmacopoeiaEPAR European Public Assessment ReportsESRA European Society of Regulatory AffairsEuropean Pharmacopoeia Commission 欧洲药典委员会FDAFDA Food and Drug AdministrationFinal Evaluation Report (FER)Free Sale Certificates (FSCs)GCP Good Clinical Practice GCP药品临床研究管理规范GLP Good Laboratory PracticeGLP 药品临床前安全性研究质量管理规范GMP Good Manufacturing PracticeGMP 药品生产质量管理规范GSP药品销售管理规范Health Sciences Authority (HSA)HSA’s Medicines Advisory Committee (MAC)IB Investigators BrochureICH International Conference for Harmonization IDMC Independent Data-Monitoring CommitteeIEC Independent Ethics CommitteeIND Investigational New DrugINN International Non-proprietary Name International Conference on Harmonization (ICH) IPC In Process ControlIRB Institutional Review BoardLICENCE HOLDERMA Marketing AuthorizationMAA Marketing Authorization ApplicationMAA上市申请MAH Marketing Authorization HolderMAH 销售许可持有者MCA Medicines Control AgencyMHW Ministry of Health and Welfare (Japan)MR Mutual RecognitionMRA 美国与欧盟的互认协议MRAs (Mutual Recognition Agreements) 互相認證同意MRFG Mutual Recognition Facilitation GroupMRP Mutual Recognition ProcedureNAS New Active SubstanceNCE New Chemical EntityNDA New Drug ApplicationNew Chemical Entities (NCEs)New Drug Applications (NDAs)NSAID Non Steroidal Anti Inflammatory DrugNTA Notice To ApplicantsOOS Out of SpecificationOTC Over the CounterPAGB Proprietary Association of Great BritainPh Eur European PharmacopoeiaPIL Patient Information LeafletPL Product License POM Prescription Only MedicinePRODUCT OWNERPSU Periodic Safety UpdatesQA Quality AssuranceQC Quality ControlRAJ Regulatory Affairs JournalRMS Reference Member StateRMS相互认可另一成员国RSD Relative Standard DeviationRx Prescription OnlySAE Serious Adverse EventSMF Site Master FileSOP Standard Operating ProcedureSOP (STANDARD OPERATION PROCEDURE)标准运作程序SPC Summary of Product CharacteristicsTherapeutic Goods Administration (TGA)USP US PharmacopoeiaVMF Veterinary Master FileVPC Veterinary Products CommitteeA.A.A Addition and Amendments 增补和修订AC Air Conditioner 空调器ADR Adverse Drug Reaction 药物不良反应AFDO Association of Food and Drug Officials食品与药品官员协会(美国)ACC Accept 接受AQL Acceptable Quality Level 合格质量标准ADNA Abbreviated New Drug Application 简化的新药申请BOM Bill of Material 物料清单BPC Bulk pharmaceutical Chemicals 原料药CBER Center for Biologics Evaluation Research生物制品评价与研究中心CFU Colony Forming Unit 菌落形成单位DMF Drug Master File 药品管理档案CDER Center for Drug Evaluation and Research药物评价与研究中心CI Corporate Identity (Image) 企业识别(形象)CIP Cleaning in Place 在线清洗CSI Consumer Safety Inspector 消费者安全调查员CLP Cleaning Line Procedure 在线清洗程序DAL Defect Action Level 缺陷作用水平DEA Drug Enforcement Administration 管制药品管理DS documentation System 文件系统FDA Food and Drug Administration食品与药品管理局(美国)GATT General Agreement on Tariffs and Trade关贸总协会GMP Good Manufacturing Practice 药品生质量管理规范GCP Good Clinical Practice 药品临床实验管理规范GLP Good Laboratory Practice 实验室管理规范GSP Good Supply Practice 药品商业质量规范GRP Good Retail Practice 药品零售业质量管理规范GAP Good Agriculture Practice 药材生产管理规范GVP Good Validation Practice 验证管理规范GUP Good Use Practice 药品使用规范HVAC Heating Ventilation Air Conditioning空调净化系统ISO International Organization for Standardization 国际标准化组织MOU Memorandum of Understanding 谅解备忘录PF Production File 生产记录用表格OTC Over the Counter (Drug) 非处方药品PLA Product License Application 产品许可申请QA Quality Assurance 质量保证QC Quality Control 质量控制QMP Quality Management Procedure 质量管理程序SDA State Drug Administration 国家药品监督管理局SMP Standard Management Procedure 标准管理程序SOP Standard Operating Procedure 标准操作程序TQC Total Quality Control 全面质量管理USA United States Pharmacopoeia 美国药典质检专业术语1. 认可的实验室 accredited laboratory2. 提前装运通知 advanced shipment notification (ASN)3. 基准确定 benchmarking4. 经营计划 business plan5. 计算机辅助设计 computer aided design (CAD)6. 计算机辅助工程 computer aided engineering (CAE)7. 校准 calibration8. 应急计划 contingency plan9. 持续改进计划/方案continuous improvement plan/program10. 合同 contract11. 控制计划 control plan12. 纠正措施计划 corrective action plan13. 不良质量成本 cost of poor quality14. 横向职能方法 cross-functional approach15. 装配性设计 design for assembly (DFA)16. 实验设计 design of experiment (DOE)17. 设计纪录 design record18. 设计责任供方 design-responsible suppliers 19. 文件document ation20. 安全关注 due care21. 设备 equipment22. 工程批准的授权engineering approved authorization23. 执行职责 executive responsibility24. 有限元分析 finite element analysis (FEA)25. 可行性 feasibility26. 先进先出 first in first out (FIFO)27. 失效模式及后果分析failure mode and effects analysis (FMEA)28. 功能验证 functional verification29. 几何尺寸与公差geometric dimensioning & tolerancing (GD&T)30. 作业指导书 job instruction31. 实验室 laboratory32. 实验室范围 laboratory scope33. 末件比较 last off part comparison34. 全尺寸检验 layout inspection35. 防错 mistake proofing36. 多方论证方法 multi-disciplinary approach37. 运行业绩 operational performance38. 预见性维护 predictive maintenance39. 超额运费 premium freight40. 预防性维护 preventive maintenance41. 解决问题 problem solving42. 程序 procedures43. 过程审核 process audit44. 过程流程图 process flow diagram flow chart45. 产品 product46. 产品实现 product realization47. 产品审核 product audit48. 项目管理 project management49. 质量功能展开 quality function deployment (QFD)50. 质量手册 quality manual51. 反应计划 reaction plan52. 外部场所 remote location53. 重复性和再现性研究repeatability and reproducibility studies54. 现场 site55. 特殊特性 special characteristics56. 分承包方 subcontractor57. 分承包方的开发 subcontractor development58. 供方 supplier59. 投标 tender60. 工具/工装 tool/tooling更衣室 Changing Room一更 First Changing Room手消室 Hands Disinfection Room气闸室 Airlock Room洁具室 Cleaning Tools Room清洗室 Cleaning Room模具室 Dies Room内包装室 Immediate Package Room安全门 Emergency Door外包清室Outer Package Removing Room存料间Storage Room of Raw Materials粉碎室 Pulverizing Room备料室 Materials Preparing Room硬胶室 Hard Capsules Filling Room软胶室 Soft Capsules Room制粒干燥室Granulating and Drying Room总混间 Blending Room中间站 Intermediate Station压片室Tablets Room Compression Room包衣室 Coating Room配浆间 Coating Mixture Preparing Room铝塑包装间Packing Room传递窗 Transferring Window外包装室 Outer Packing Room蒸馏水室 Water Purifying Room质检室 Quality Control Room浓配室 Concentrated Solution Room稀配室 Diluted Solution Room灌封室Filling and Sealing Room存瓶室 Ampul Storage Room洗瓶室 Ampul Cleaning Room灭菌间 Sterilizing Room灯检室 Light Inspection Room粉针室 Lyophilized Sterile Powder Room冷冻干燥机 LyophilizerUrine Analyzer 尿液分析仪blood sugar(glucose ) analyzer血糖分析仪test strip 测试条reagent 试剂Semi-automatic Biochemical Analyzer半自动生化分析仪Automatic Blood Cell Analyzer全自动血细胞分析仪Urine sediments analyzer尿沉渣Bio-safety Cabinet 生物安全柜Incubator培养箱High Frequency Electrotome 高频电刀shadowless lamp无影灯High speed refrigerated centrifuge高速冷冻离心机hot air sterilizer热空气消毒箱microbiological incubator微生物培养箱Halogen light 卤素灯disposable sterile injector 一次性无菌注射针injection set注射器disposable venous infusion needle一次性静脉输液针disposable infusion set 一次性使用输液器blood transfusion set输血器infusion bag液袋urine drainage bag集尿袋blood bag血袋medical catheter医用导管stainless steel needle不锈钢医用针管blood taking needle采血针needle destroyer针头销毁器automatic packer自动纸塑包装机scalp vein set头皮针uniprocessor version单机版network version网络版macromolecule-solvent 高分子溶解的macromolecule cold accumulation 高分子蓄冷cold treatment冷疗法ice pack冰袋eyeshade 眼罩Medical injection pump医用灌注泵lithotrite 碎石机extracorporeal shock wave lithotrite体外冲击碎石机Ballistic intracroporeal lithotrite气压冲击体内碎石机Laparoscope 腹腔镜Urology 泌尿外科kidney stones 肾结石Multi-parameter monitor, 多参数监护仪maternal monitor/fetal monitor母亲/胎儿监护仪ICU monitor 重症监护仪anesthetic equipment 麻醉机respirator呼吸机electronic colposcope 电子阴道镜smog absorber烟雾吸收器digital film room 数字胶片室Permanent Magnet Open Magnetic Resonance system 永磁开放式磁共振系统Ultrasonic Color Doppler Diagnostic system彩色超声多普勒诊断系统Mobile CT system 移动CT系统X-ray Mammary Machine 乳腺X线机Mammography乳腺high precision Stereotaxic 高精度脑立体定向仪portable Type-B ultrasonic 便携式B超Sterilization and Disinfection Equipment消毒灭菌设备Radiotherapeutic equipment.放射疗法设备pharmaceutical equipments.制药设备horizontal pressurized steam sterilizer普通卧式压力蒸汽灭菌器medical electronic linear accelerator医用电子直线加速器high frequency X-rays diagnostic machine高频X射线诊断机simulated positioner模拟定位机high frequency mobile X-rays machine高频移动X射线机暖通专业词汇中英文对照(一)ahu air hundling unit 空调箱air conditioning load空调负荷air distribution气流组织air handling unit 空气处理单元air shower 风淋室air wide pre.drop空气侧压降aluninum accessaries in clean room 洁净室安装铝材as-completed drawing 修改竣工图ayout 设计图blass stop valve 铜闸阀canvas connecting termingal 帆布接头centigrade scale 摄氏温度chiller accessaries 水冷柜机排水及配料chiller asembly 水冷柜机安装工费chiller unit 水冷柜机基础clean bench 净化工作台clean class 洁净度clean room 洁净室无尘室correction factor修正系数dcc dry coll units 干盘管district cooling 区域供冷direct return system异程式系统displacement ventilation置换通风drawn No.图号elevation立面图entering air temp进风温度entering water temp进水温度fahrenheit scale 华氏温度fan coil unit 风机盘管ffu fan filter units 风扇过滤网组final 施工图flow velocity 流速fresh air supply 新风供给fresh air unit 新风处理单元ground source heat pump地源热泵gross weight 毛重heating ventilating and air conditioning供热通风与空气调节hepa high efficiency pariculate air 高效过滤网high efficiency particulate air filters高效空气过滤器horizontal series type水平串联式hot water supply system生活热水系统humidity 湿度hydraulic calculation水力计算isometric drawing轴测图leaving air temp 出风温度leaving water temp出水温度lood vacuum pump中央集尘泵mau make up air hundling unit schedule 外气空调箱natural smoke exhausting自然排烟net weight 净重noise reduction消声nominal diameter 公称直径oil-burning boiler燃油锅炉one way stop peturn valve 单向止回阀operation energy consumption运行能耗pass box 传递箱particle sizing and counting method 计径计数法Piping accessaries 水系统辅材piping asembly 配管工费plan 平面图rac recirculation air cabinet unit schedule循环组合空调单元ratio controller 比例调节器ratio flow control 流量比例控制ratio gear 变速轮 ratio meter 比率计rational 合理性的,合法的;有理解能力的rationale (基本)原理;原理的阐述rationality 有理性,合理性rationalization proposal 合理化建义ratio of compression 压缩比ratio of expansion 膨胀比ratio of run-off 径流系数ratio of slope 坡度ratio of specific heat 比热比raw 生的,原状的,粗的;未加工的raw coal 原煤 raw cotton 原棉raw crude producer gas 未净化的发生炉煤气raw data 原始数据raw fuel stock 粗燃料油raw gas 未净化的气体real gas 实际气体realignment 重新排列,改组;重新定线realm 区域,范围,领域real work 实际工作ream 铰孔,扩孔rear 后部,背面,后部的rear arch 后拱rear axle 后轴rear-fired boiler 后燃烧锅炉rear pass 后烟道rearrange 调整;重新安排[布置]rearrangement 调整,整顿;重新排列[布置] reason 理由,原因;推理reasonable 合理的,适当的reassembly 重新装配reaumur 列氏温度计reblading 重装叶片,修复叶片recalibration 重新校准[刻度]recapture 重新利用,恢复recarbonation 再碳化作用recast 另算;重作;重铸receiving basin 蓄水池receiving tank 贮槽recentralizing 恢复到中心位置;重定中心;再集中receptacle 插座[孔];容器reception of heat 吸热recessed radiator 壁龛内散热器,暗装散热器recharge well 回灌井reciprocal 倒数;相互的,相反的,住复的reciprocal action 反复作用reciprocal compressor 往复式压缩机reciprocal feed pump 往复式蒸汽机reciprocal grate 往复炉排reciprocal motion 住复式动作reciprocal proportion 反比例reciprocal steam engine 往复式蒸汽机reciprocate 往复(运动),互换reciprocating 往复的,来回的,互相的,交替的reciprocating ( grate ) bar 往复式炉排片reciprocating compressor 往复式压缩机reciprocating condensing unit 往复式冷冻机reciprocating packaged liquid chiller往复式整体型冷水机组reciprocating piston pump 往复式活塞泵reciprocating pump 往复泵,活塞泵reciprocating refrigerator 往复式制冷机recirculate 再循环recirculated 再循环的recirculated air 再循环空气[由空调场所抽出,然后通过空调装置,再送回该场所的回流空气]recirculated air by pass 循环空气旁路recircilated air intake 循环空气入口recirculated cooling system 再循环冷却系统recirculating 再循环的,回路的recirculating air duct 再循环风道recirculating fan 再循环风机recirculating line 再循环管路recirculating pump 再循环泵recirculation 再循环recirculation cooling water 再循环冷却水recirculation ratio 再循环比recirculation water 再循环水reclaim 再生,回收;翻造,修复reclaimer 回收装置;再生装置reclamation 回收,再生,再利用reclamation of condensate water蒸汽冷凝水回收recombination 再化[结]合,复合,恢复recommended level of illumination 推荐的照度标准reconnaissance 勘察,调查研究record drawing 详图、大样图、接点图recording apparatus 记录仪器recording barometer 自记气压计recording card 记录卡片recording facility 记录装置recording liquid level gauge 自动液面计recording paper of sound level 噪声级测定纸recording pressure gauge 自记压力计recording water-gauge 自记水位计recoverable 可回收的,可恢复的recoverable heat 可回收的热量recoverable oil 可回收的油recoverable waster heat 可回收的废热recovery plant 回收装置recovery rate 回收率relief damper 泄压风门return air flame plate回风百叶。
某公司已过新版GMP认证洁净厂房验证模版(中英文)汇总
Installation Qualification Protocol洁净室安装确认方案System No. 系统编号: CLR-01Index 目录1.PURPOSE目的 (3)2.SCOPE范围 (3)3.RESPONSIBILITY职责 (3)4.REGULATION AND GUIDANCE 法规和指南 (3)5.ABBREVIATIONS缩略语 (3)6.SYSTEM DESCRIPTION 系统描述 (3)7.GOOD DOCUMENTATION PRACTICE文件管理规范 (5)8.TEST LIST测试列表 (6)9.PERSONNEL IDENTIFICATION人员确认 (6)10.PROCEDURE过程 (7)10.1先决条件 (7)10.2文件确认 (10)10.3图确认 (11)10.4房间组件检查 (13)10.5仪器仪表校验 (15)10.6洁净室建造装修检查 (17)10.7电器安装检查 (22)11. DEVIATION REPORT偏差报告 (28)1. Purpose目的本安装确认方案的目的是测试、检查和洁净室是按照相应设计要求和供应商的建议进行安装的。
安装确认的测试和检查的结果将按照该验证方案进行记录。
安装确认将确定直接影响系统的关键部件被正确地安装,并符合设计文件需求;确定支持文件、质量文件在现场。
测试和检查的结果将按照该验证方案进行记录。
2. Scope范围本方案确定了***********公司口服固体项目车间的洁净室(位号:***********)的安装确认。
3. Responsibility职责4. Regulation and Guidance 法规和指南(SFDA) GMP 2010版中国药典2010版现行版ISPE指南5“调试和确认”洁净厂房设计规范GB13554-925. Abbreviations缩略语6. System Description 系统描述口服固体制剂的洁净室包括以下级别D级区对产品无影响的房间无需验证。
q7A-GMP中英文对照
Q7a (中英文对照)FDA 原料药GMP 指南Table of Contents 目录1. INTRODUCTION 1. 简介1.1 Objective 1.1目的1.2 Regulatory Applicability 1.2法规的适用性1.3 Scope 1.3范围2. QUALITY MANAGEMENT 2.质量管理2.1 Principles 2.1总则2.2 Responsibilities of the Quality Unit(s) 2.2质量部门的责任2.3 Responsibility for Production Activities 2.3生产作业的职责2.4 Internal Audits (Self Inspection) 2.4内部审计(自检)2.5 Product Quality Review 2.5产品质量审核3. PERSONNEL 3. 人员3.1 Personnel Qualifications 3.人员的资质3.2 Personnel Hygiene 3.2 人员卫生3.3 Consultants 3.3 顾问4. BUILDINGS AND FACILITIES 4. 建筑和设施4.1 Design and Construction 4.1 设计和结构4.2 Utilities 4.2 公用设施4.3 Water 4.3 水4.4 Containment 4.4 限制4.5 Lighting 4.5 照明4.6 Sewage and Refuse 4.6 排污和垃圾4.7 Sanitation and Maintenance 4.7 卫生和保养5. PROCESS EQUIPMENT 5. 工艺设备5.1 Design and Construction 5.1 设计和结构5.2 Equipment Maintenance and Cleaning 5.2 设备保养和清洁5.3 Calibration 5.3 校验5.4 Computerized Systems 5.4 计算机控制系统6. DOCUMENTATION AND RECORDS 6. 文件和记录6.1 Documentation System and Specifications6.1 文件系统和质量标准 6.2 Equipment cleaning and Use Record 6.2 设备的清洁和使用记录6.3 Records of Raw Materials, Intermediates, API Labeling and Packaging Materials6.3 原料、中间体、原料药的标签和包装材料的记录 6.4 Master Production Instructions (Master Production and Control Records)6.4 生产工艺规程(主生产和控制记录) 6.5 Batch Production Records (Batch Production and Control Records) 6.5 批生产记录(批生产和控制记录)6.6 Laboratory Control Records 6.6 实验室控制记录6.7 Batch Production Record Review 6.7批生产记录审核7. MATERIALS MANAGEMENT 7. 物料管理7.1 General Controls 7.1 控制通则7.2 Receipt and Quarantine 7.2接收和待验7.3 进厂物料的取样与测试7.3 Sampling and Testing of IncomingProduction Materials7.4 Storage 7.4储存7.5 Re-evaluation 7.5复验8. 生产和过程控制8. PRODUCTION AND IN-PROCESSCONTROLS8.1 Production Operations 8.1 生产操作8.2 Time Limits 8.2 时限8.3 In-process Sampling and Controls 8.3 工序取样和控制8.4 中间体或原料药的混批8.4 Blending Batches of Intermediates orAPIs8.5 Contamination Control 8.5 污染控制9. PACKAGING AND IDENTIFICATION9. 原料药和中间体的包装和贴签 LABELING OF APIs ANDINTERMEDIATES9.1 General 9.1 总则9.2 Packaging Materials 9.2 包装材料9.3 Label Issuance and Control 9.3 标签发放与控制9.4 Packaging and Labeling Operations 9.4 包装和贴签操作10. STORAGE AND DISTRIBUTION 10.储存和分发10.1 Warehousing Procedures 10.1 入库程序10.2 Distribution Procedures 10.2 分发程序11. LABORATORY CONTROLS 11.实验室控制11.1 General Controls 11.1 控制通则11.2 Testing of Intermediates and APIs 11.2 中间体和原料药的测试 11.3 Validation of Analytical Procedures 11.3 分析方法的验证11.4 Certificates of Analysis 11.4 分析报告单11.5 Stability Monitoring of APIs 11.5 原料药的稳定性监测11.6 Expiry and Retest Dating 11.6 有效期和复验期11.7 Reserve/Retention Samples 11.7 留样12. V ALIDATION 12.验证12.1 Validation Policy 12.1 验证方针12.2 Validation Documentation 12.2 验证文件12.3 Qualification 12.3 确认12.4 Approaches to Process Validation 12.4 工艺验证的方法12.5 Process Validation Program 12.5 工艺验证的程序12.6 Periodic Review of Validated Systems 12.6验证系统的定期审核12.7 Cleaning Validation 12.7 清洗验证12.8 Validation of Analytical Methods 12.8 分析方法的验证13. CHANGE CONTROL 13.变更的控制14. REJECTION AND RE-USE OF14.拒收和物料的再利用 MATERIALS14.1 Rejection 14.1 拒收14.2 Reprocessing 14.2 返工14.3 Reworking 14.3 重新加工14.4 Recovery of Materials and Solvents 14.4 物料与溶剂的回收14.5 Returns 14.5 退货15. COMPLAINTS AND RECALLS 15.投诉与召回16. CONTRACT MANUFACTURERS (INCLUDING LABORATORIES)16.协议生产商(包括实验室)17. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS17.代理商、经纪人、贸易商、经销商、重新包装者和重新贴签者17.1 Applicability 17.1适用性17.2 Traceability of Distributed APIs and Intermediates17.2已分发的原料药和中间体的可追溯性 17.3 Quality Management 17.3质量管理17.4 Repackaging, Relabeling, and Holding of APIs and Intermediates 17.4原料药和中间体的重新包装、重新贴签和待检17.5 Stability 17.5稳定性17.6 Transfer of Information 17.6 信息的传达17.7 Handling of Complaints and Recalls 17.7 投诉和召回的处理17.8 Handling of Returns 17.8 退货的处理18. Specific Guidance for APIs Manufactured by Cell Culture/Fermentation 18. 用细胞繁殖/发酵生产的原料药的特殊指南18.1 General 18.1 总则18.2 Cell Bank Maintenance and Record Keeping18.2细胞库的维护和记录的保存18.3 Cell Culture/Fermentation 18.3细胞繁殖/发酵18.4 Harvesting, Isolation and Purification 18.4收取、分离和精制18.5 Viral Removal/Inactivation steps18.5 病毒的去除/灭活步骤19. APIs for Use in Clinical Trials19. 用于临床研究的原料药 19.1 General 19.1 总则19.2 Quality 19.2 质量19.3 Equipment and Facilities 19.3 设备和设施19.4 Control of Raw Materials 19.4 原料的控制19.5 Production 19.5 生产19.6 Validation 19.6 验证19.7 Changes 19.7 变更19.8 Laboratory Controls 19.8 实验室控制19.9 Documentation 19.9 文件20. Glossary 20 . 术语Q7a GMP Guidance for APIsQ7a 原料药的GMP 指南1. INTRODUCTION 1. 简介1.1 Objective 1.1目的This document is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the quality and puritycharacteristics that they purport, or arerepresented, to possess.本文件旨在为在合适的质量管理体系下制造活性药用成分(以下称原料药)提供有关优良药品生产管理规范(GMP )提供指南。
制药质量手册-英文
Good Manufacturing Practice (cGMP) Pharmaceutical Inspectorate For Medicinal ProductsControl of PharmaceuticalsPage 1 of 34SOP no. QM-01/02Supersedes version - 01Institute for Standardization and Control of PharmaceuticalsQuality ManualGood Manufacturing Practice (cGMP) Pharmaceutical InspectorateFor Medicinal ProductsSignatureDateJob FunctionNameDirector, Institute forStandardization and Control ofPharmaceuticalsMimi KaplanPh.D.Head ofGMP InspectorateRami Kariv,Ph.D.Quality Assurance ManagerSarah CovrigaroGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal Products Control of PharmaceuticalsPage 2 of 34SOP no. QM-01/02Supersedes version - 01Table of ContentsNo. Section Page(i) General 3(ii) References 41. Scope 52. Definitions 63. Administrative Requirements 74. Independence, Impartiality, Integrity 85. Confidentiality 96. Organization and Management 107. Quality System 158. Personnel Training and Qualification 189. Facilities and Equipment 2010. Inspection Methods and Procedures 2111. Handling Inspection Samples 2312. Records, Documents and Data Controls 2413. Inspection Reports, Issue, Withdrawal of Licenses, GMP Certificates2514. Sub-contracting 2715. Quality Improvement & Corrective and Preventive Action (CAPA)2816. Quality Audits 2917. Complaints and Appeals 3018. Periodic Review, Quality Indicators and Statistical Techniques3119. Liaison with the Institute Laboratories 3220. Co-operation 3221. Handling Suspected Quality Defects and Rapid Alert System3322. Publications 34Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 3 of 34SOP no. QM-01/02Supersedes version - 01(i) GeneralThe numbering of this quality manual is designed to address each of the sections in the document EN 45004, General Criteria for the Operation of Various Types of Bodies Performing Inspection, as well as integrating the body of the content of the PIC/S document “Recommendation on Quality System Requirements for Pharmaceutical Inspectorates” PI 002-3, September 2007.This manual documents the Israeli Ministry of Health GMP Inspectorate's Quality System. The manual is intended to demonstrate that the GMP Inspectorate has the ability, integrity and resources to perform those activities required of it, as defined in the manual. The manual also addresses procedures for maintaining the quality system, including audits and periodic, formal review of quality indicators.The activity described in this manual is covered by approved Standard Operating Procedures (SOPs) that provide precise instructions on how to perform anddocument the relevant activity.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 4 of 34SOP no. QM-01/02Supersedes version - 01(ii) ReferencesThis Quality Manual is based on the following normative standards and references. The content of the manual is intended to comply with the spirit and current understanding and interpretation of the referenced documents.1. EN 45004: 1995, European StandardGeneral Criteria for the operation of various types of bodiesperforming inspection2. PIC/S, Pharmaceutical Inspection Co-operation SchemeRecommendation on Quality System Requirements for PharmaceuticalInspectorates, PI 002-3, September 2007.3. Compilation of Community Procedures on Inspection and Exchange of InformationEC/EMEA 2006Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 5 of 34SOP no. QM-01/02Supersedes version - 011. ScopeThe scope of this Quality Manual covers all those activities that fall under the responsibility of the GMP Inspectorate at the Ministry.The Pharmaceutical Division of The Ministry is responsible for ensuring the safety, efficacy and quality of therapeutic goods supplied in Israel. The Pharmaceutical Division regulates finished pharmaceuticals (pharmaceutical products) and Active Pharmaceutical Ingredients (APIs) for human, biological and veterinary drugs. The authority for these activities is enacted in the legislation of the Pharmacists ordinance [New Version] 1981, Pharmacists Regulations (Medical Products) 1986, Pharmacists Regulations [Good Manufacturing Practice], 2008.The scope of activities covered by the inspectorate includes:•Human Pharmaceutical Drug Products•Biological Pharmaceutical Products•Plasma Products•Veterinary Drug Products•Active Pharmaceutical Ingredients (APIs)•Pre-market approval for a new drug (innovative or generic) where it is determined that there is a need for inspection•Approval for initiation of manufacturing of any of the above products in a new facility or site•Approval for manufacture of Investigational Medical Products (Phase III)The GMP inspectorate has at its disposal at any time, an up to date list of approved manufacturers inspected periodically by the inspectorate.Good Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsControl of PharmaceuticalsPage 6 of 34SOP no. QM-01/02Supersedes version - 012. DefinitionsQuality System The sum of all that is necessary to implement an organization’squality policy and meet quality objectives. It includesorganizational structure, responsibilities, procedures, systems,processes and resources.Quality Indicators Selected data intended to be periodically observed to assist inassessing trends in performance.Israeli GMP Inspectorate The national body responsible for co-ordinating and carrying out pharmaceutical GMP inspections of pharmaceutical manufacturers, issue or withdrawal of Manufacturer's authorization and GMP certificates, providing advice and handling suspected quality defects.Authorization For the purposes of this document, an authorization is defined as"Manufacturer's authorization" issued by the Ministry of Healthaccording to Pharmacists Regulation (Good ManufacturingPractice) 2008 that provides authorization to manufacturemedicinal products .Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 7 of 34SOP no. QM-01/02Supersedes version - 013. Administrative RequirementsThe Institute for Standardization and Control of Pharmaceuticals (here and after referred to as "The Institute") is a part of The Pharmaceutical Division of the Israeli Ministry of Health and is responsible for enforcement of current Good Manufacturing Practice (cGMP) regulations in Israel. The General Director of the Israeli Ministry of Health confers the legal authority for supervision of pharmaceutical facilities and issuing certificates of compliance with cGMP upon the Director of the Institute for Standardization and Control of Pharmaceuticals. This is administered through application of the General Director's directive 15/03. The GMP Inspectorate (The Inspectorate) is an independent unit functioning within the Institute and reporting to the Institute Director.The Inspectorate's activities and guidelines as how to implement these functions are documented together with a detailed description of the scope of activity for which it is competent in approved Standard Operation Procedures (SOPs). The Quality Manual is available to the general public on the Ministry of Health's website. The precise scope of each inspection or related activity is determined by the nature of the work involved and is determined in writing prior to initiation of the inspection based on review of relevant documentation.The Inspectorate's liability is assumed by the State of Israel in accordance with national laws. The Inspectorate is part of the Ministry of Health and as such provides inspection services to the Ministry of Health. As such reporting requirements and work assignments are governed by applications made by companies to the Ministry of Health and / or ongoing GMP compliance activities in accordance with the Inspectorate’s Standard Operating Procedures.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 8 of 34SOP no. QM-01/02Supersedes version - 014. Independence, Impartiality and IntegrityEvery effort shall be made to ensure that activities of the Israeli cGMP Compliance Inspectorate are not compromised by conflict of interest or improper influence. The Inspectorate is an independent organization with no financial dependence on those institutions that are inspected by the Inspectorate.Inspectorate personnel shall be free from any commercial, financial or other pressures, which may affect their judgment. Procedures shall be in place to ensure that persons, companies or organizations external to the Inspectorate cannot influence the results of the inspections carried out by the Inspectorate.The Inspectorate shall be impartial when performing an assessment of suitability for GMP requirement. In this regard, Inspectorate personnel are required to comply with the official conduct requirements of the Public Service Act. The decision on whether or not to issue a manufacturer's authorization and/or GMP certificate shall be based solely on documented, professional considerations resulting from observations and / or other evidence collected during the performance of the suitability assessment.The cGMP Inspectorate may not provide consulting services to GMP authorized/approved clients, or to clients seeking GMP authorization/approval. Likewise, the cGMP Inspectorate may not make recommendations regarding particular vendors, consultants or other service providers beyond a general statement that they consider a company may require the assistance of a certain type of provider.The Inspectorate may participate in regular meetings with various industryrepresentative groups. Such meetings shall be open to all representatives of theparticular group and shall preclude any influence on the issue of GMP or quality certification. Such meetings may be held in order to obtain industry input prior to policy making. However, at the end of the day the policy will be determined based on the Inspectorate's professional judgment and after a survey of current industry andregulatory practice.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 9 of 34SOP no. QM-01/02Supersedes version - 015. ConfidentialityThe confidentiality of commercial information shall be respected at all times. The Inspectorate shall ensure the confidentiality of information obtained in the course if its inspection activities and related duties. Proprietary rights and intellectual property rights shall be protected and respected.Where appropriate access to commercial information shall be restricted to those persons within the Inspectorate that require said information for the performance of their professional duties. Such information shall be stored in restricted access areas. Likewise, personnel will make every effort to protect information stored in electronic format or on magnetic media or in any other computerized format.Every public servant is required to sign on a confidentiality agreement as a condition for entering public service. This agreement requires them to maintain confidentiality of any information that comes to their knowledge in fulfillment of their public duties.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 10 of 34SOP no. QM-01/02Supersedes version - 016. Organization and Management (Management Responsibility)OrganizationThe organizational chart of the inspectorate is provided below. The Head of the GMP Inspectorate reports directly to the Director of the Institute. Inspectors report directly to the Head of the Inspectorate. Expert inspectors are usually managers in other units of the Institute, reporting to the Institute Director. When participating in an inspection team they report directly to the Head of GMP Inspectorate.GMP Inspectorate Organization ChartControl of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 11 of 34SOP no. QM-01/02Supersedes version - 01Management ResponsibilityThe Director of the Institute is responsible for the overall management of the GMP Inspection program and as such, for the overall management of the GMP Inspectorate.The Head of GMP Inspectorate is directly responsible for management of the Inspectorate. If absent from the office for an extended period of time, responsibility for the management of the Inspection shall be delegated to another suitably qualified member of the Inspectorate. The authority for such delegation will be documented in the person's job description. In such an event, the Acting Head, GMP Inspectorate will be responsible for all inspection related activities for which the Head is normally responsible.Based on his / her professional discretion, the Head, GMP Inspectorate, may delegate responsibility for specified activities to other Inspectorate personnel. The responsibility for making certain decisions may be delegated to specific review panels, the composition of which is determined by on an ad hoc basis. When a responsible person is absent from work and responsibility for a particular activity has not been formally delegated, delegation shall automatically be upwards, i.e. to the person's supervisor etc.The Director of the Institute is reporting to The Director of the Pharmaceutical Division, who in turn reports to the Deputy General Director of the Ministry.The responsibilities and authority of Inspectorate personnel are described in written job descriptions for each position in the Inspectorate. Job descriptions are signed by the staff member and by the Director of the Institute, indicating that they are both aware and agree to the scope of activities described therein. Job descriptions are filed in each staff member's personal file held by the Institute's personnel department.Inspectorate personnel must have appropriate educational qualification, training and experience or suitable combination of these factors to enable them to perform their duties. Generally minimum educational requirements are for an academic degree in a life science (e.g. biology, microbiology, immunology etc.), pharmacy or chemistry. Practical experience in the pharmaceutical or related industry at a management level is considered an advantage although is not necessarily a pre-requisite for employment in the Inspectorate.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 12 of 34SOP no. QM-01/02Supersedes version - 01The inspectorate is currently staffed by the Head of GMP Inspectorate, GMP Inspector, 5 part time experts, QA Manager and supported by administrative staff of the Institute. The Inspectorate is located in the Givat Shaul neighbourhood close to the entrance to Jerusalem.The responsibilities of the Director include but are not necessarily limited to:- Overall management of the GMP Compliance Inspectorate- Serving as the management representative for the Quality System- Ensuring the availability of adequate resources for implementation and maintenance of the Quality System- Intervening and assisting in resolving ongoing compliance issues where resolution between the Inspectorate and industry has not reached an acceptable conclusion- Setting Policy for the requirement from the industry and standards of the Inspectorate - Liaison with other regulatory and certification bodies, including PIC/S- Liaison with industry representatives and bodies where appropriate- Ensuring availability of adequate resources such that the inspectorate can conduct their activities in a professional and orderly manner- Decision on deferral or rejection of Quality Certificates of medicinal product, Manufacturer's authorizations or GMP Certificates.The responsibilities of the Head, GMP Inspectorate include but are not necessarily limited to: - Setting policy for, ensuring and overseeing Quality Assurance of all activities performed by the GMP Compliance Inspectorate- Ensuring the existence of and implementation of an annual training schedule as well as evaluating requests for training- Arranging, planning and conducting inspections in Israel and, where required, abroad - documenting inspections- Approval of authorizations and certificates: recommending the issue, deferral or rejection of manufacturer's authorizations or GMP Certificates.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 13 of 34SOP no. QM-01/02Supersedes version - 01- Ensuring impartiality of the inspection group such that the outcome of audits is not compromised by conflict of interest or improper influence.- Handling complaints.- Review and approval of SOPs and other documentation related to the activities of the Inspectorate as appropriate.- Ensuring the performance of management reviews and providing solutions to ongoing or recurrent problems presented in said reviews.- Providing limited advice to industry, and advice to other departments in the Ministry of Health.- Participating in internal audits, for cause inspections etc.- Participating on committees or panels as necessary.- Assessing evidence of GMP for overseas manufacturers.The responsibilities of the Quality Assurance Manager shall include:- Establishing and maintaining the Inspectorate's Quality System.- Establishing and maintaining an internal audit program.- Establishing and monitoring Quality metrics regarding the effectiveness of the Quality System to The Institute's management review and as a basis for continuousimprovement.- Establishing, maintaining and monitoring correction of items entered into the Quality System CAPA program.- Ensuring that pre-approval and ongoing compliance inspections are performed in a timely manner.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 14 of 34SOP no. QM-01/02Supersedes version - 01Any decisions relating to rejection of an authorization application or the suspension of an authorization shall be made by the Director of the Institute.Inspections that require a specialized knowledge shall be restricted to inspectors with that knowledge, or specialists, e.g. persons from the Institute laboratories may be included in inspection teams to provide professional advice.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 15 of 34SOP no. QM-01/02Supersedes version - 017. Quality SystemThe primary purpose of the Quality System is to ensure that adequate quality standards are maintained in all of the Inspectorate's functions and duties. The Quality System requirements for the Israeli GMP Inspectorate should include and address all activities involved in the GMP inspection process.The GMP Inspectorate has a quality policy that defines and documents the objectives and commitment to quality. The quality policy is used as an educational resource and must be understood and followed by all personnel working under the Inspectorate's authority.7.1. Quality PolicyThe quality policy of the GMP inspectorate is as follows:The Inspectorate is committed to maintaining high performance standards, meeting the expectations of the Ministry and the general public in safeguarding public health byensuring the uninterrupted supply of safe and efficacious medicinal products.The Institute's GMP Inspectorate is committed to operating an effective quality system that complies with the PIC/S recommendations (PI 002-3, September 2007). Thesystem shall be such that it enables the Inspectorate to maintain the capability toperform its technical functions satisfactorily.The Inspectorate will do all in its power to meet its quality goals and to protect and be deserving of its respected national and international reputation.The Inspectorate will define and document their responsibilities and reporting structure in written approved standard operating procedures.The Inspectorate understands, is familiar with and is committed to the principle of continuous improvement in all areas of activity and has procedures in place to ensure that areas of weakness are systematically identified and acted upon in a timelymanner.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 16 of 34SOP no. QM-01/02Supersedes version - 01Inspectorate personnel should be familiar with the Quality Policy and committed to the following principles that are to be complied with in performance of any and all of their duties: The Quality Policy of the GMP Inspectorate is as follow:M aintain integrity and impartiality.Be consistent in decisions and assessments.Be polite, respectful, firm, fair and just.Respect the rights of all persons with whom they have contact during the performance of their duties.Maintain strict confidentiality of privileged information.Undertake continuous professional development, ensure that they are updated and aware of changes in standards, current practices and technologies and participate in appropriatetraining so as to ensure that inspectional standards are state-of-the art.7.2. Documentation SystemThe quality system is documented in a comprehensive set of Standard Operating Procedures (SOPs), of which, this quality manual forms an integral part.One of the main procedures in the quality system is the Documentation and Change Control policy. This SOP ensures that only current, approved copies of controlled documents are available to all relevant personnel. Changes in controlled documents are reviewed and approved by relevant functions within the organization and result in re-issue of the document to all concerned persons with appropriate re-training. Where changes are made in a document there is a method for identifying changes from the previous version where such exists. The master copy of any superseded document is archived for a pre-determined period and all other copies are withdrawn from use in a timely and controlled manner.As part of the documentation policy, there is a procedure for maintaining records relating to the activities of the GMP Inspectorate. The system should include any relevant documents including those received from authorization applicants and authorization holders where appropriate. A system to ensure the confidentiality of commercial information and intellectual property must be implemented and strictly maintained. Where required, records will be shared under the exchange of information procedures and arrangements between NationalControl of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 17 of 34SOP no. QM-01/02Supersedes version - 01Pharmaceutical Inspectorates and Mutual Recognition Partners, bearing in mind that the confidentiality requirements are incumbent on such partners and arrangements. Records must be handled in a manner that ensures they can be retained for a pre-determined period of time, consistent with any legal requirements and in such a manner as to provide prevent any damage or loss.7.3. Internal auditAs part of the quality system internal audits are routinely performed in accordance with an approved procedure to verify compliance with this manual, with the Ministry's Inspection Manual and with the Inspectorate's SOPs. Internal audits are intended to verify the effectiveness of the quality system and may be performed by the Quality Assurance representative or by an appropriately qualified, independent, external auditor, in which case the auditor's credentials will be maintained on file.Where discrepancies or deviations in the quality system or performance of inspection are identified, either as the result of internal audits, complaints from the public or any other source, a Corrective and Preventive Actions (CAPA) procedure is in place to ensure that the non-conformity is registered, appropriate actions taken and follow-up performed to ensure that the actions are implemented and to measure their effectiveness.7.4 Management ReviewManagement review is performed at least annually to review the quality system and ensure its continuing suitability and effectiveness. The results of the reviews are documented and followed up, including the setting of quality goals for the immediate future. Subsequent reviews address the implementation or failure thereof, of the goals determined at the previous review.Control of PharmaceuticalsGood Manufacturing Practice (cGMP)Pharmaceutical InspectorateFor Medicinal ProductsPage 18 of 34SOP no. QM-01/02Supersedes version - 018. Personnel Training and QualificationThe GMP Inspectorate has a sufficient number of permanent personnel with the necessary expertise to carry out the volume and range of work demanded by its defined functions and duties. Personnel responsible for inspection must have appropriate qualifications, training, experience and knowledge of cGMP requirements, guidelines and expectations to enable them to perform the inspection and review functions required of them. This includes knowledge of the technologies used for manufacturing pharmaceutical products, of the methods of use of the products and of problems that may arise, including injury or harming of public health as a result of failure to meet the regulations. Personnel must understand and be fully conversant with the consequences of deviations that occur or may occur during the production, distribution or use of these products.The authority for supervision of pharmaceutical facilities and issuing certificates of compliance with cGMP is conferred upon the Director of the Institute by the General Director of the Ministry of Health. The GMP Inspectorate is a part of the Institute reporting to the Director.A pre-requisite for joining the GMP inspection team is a scientific background. Allinspectors have a relevant academic degree as a minimum requirement.Staff responsible for inspection must have, apart from the above mentionedqualifications, the training and experience, as well as a satisfactory knowledge of thecGMP regulations and requirements for the inspections to be conducted. This includes understanding current interpretation of the requirements as they pertain to specificoperations and product types. Personnel are expected to have the ability to make professional judgments as to conformity with the requirements based on inspectionalfindings and to prepare detailed reports based on those findings.Inspectors are provided with on-the-job training including participating in training courses provided by foreign inspectorates as well as training courses provided by industryexperts. As part of their training experience, inspectors may participate, as observers inGMP inspections conducted by FDA and European agencies in Israeli facilities. All。
某制药公司压缩空气设备验证文件(DOC 30页)
验证文件目录一、验证项目建议表 (2)二、验证小组人员名单 (3)三、验证方案 (3)1概述 (4)2范围 (4)3.验证方案制定依据 (4)4验证目的………………………………………………1 45 职责………………………………………………………………………验证相关文件 (4)6验证内容 (5)6.1安装确认 (5)6.1.1包装确认 (5)6.1.2设备确认 (5)6.1.3资料确认 (5)6.1.4设备材质确认 (6)6.1.5环境状况确认 (6)6.1.6公用介质确认 (6)6.1.7安装过程确认 (6)6.2运行确认 (7)6.3性能确认 (7)6.4变更控制 (8)6.5验证结果评定与结论 (8)7.验证进度安排 (8)四、验证报告 (9)五、验证过程记录 (10)六、验证报告批准证书…………………………………………………………验证项目建议表编号:SMP26-057/01-03/01验证小组名单表编号:SMP26-057/01-04/01验证方案编号:SMP26-057/01-05/011.概述本系统由一台无油活塞式空压机,冷冻式干燥器、高压出气罐和空气过滤器(初级过滤、一级过滤及二级过滤)三级构成。
使用时压缩空气经进气过滤器滤去尘埃、杂质后,最后通过高效空气过滤器滤掉尘、油等杂质后供用户气动系统使用。
本系统产品严格按ISO1217,ISO7183,ISO8573.1标准设计制造,具有气量足,压缩空气洁净,为全封闭结构,低噪音,振动小,重量轻,占地面积小,操作方便,易损件少,运行效率高,无需安装基础,空车过久自动停机, 需要时自动启动,节约电力,实现24小时无人看守连续运转等特点。
1基本情况:空气压缩机设备1编号:设备名称:活塞式空气压缩机设备型号:W-1.3/30数量:一台生产厂家:沈阳压缩机有限公司使用部门:塑瓶输液车间储气罐:设备编号:设备名称:压缩空气储气罐设备型号:C-1/3.0数量:一台生产厂家:大连昌丰气体设备有限公司使用部门:塑瓶输液车间1.2主要技术参数压缩空气产量:3m³/min。
FDA-GMP中英文对照标准版
DIRECTION OF GMP (GOOD MANUFACTURING PRACTICE )OF RAW MATERIALS BY FDATable of Contents 目录1. INTRODUCTION1.1 Objective 目的1.2 Regulatory Applicability法规的适用性1.3 Scope 范围2. QUALITY MANAGEMENT .质量管理2.1 Principles 总则2.2 Responsibilities of the Quality Unit(s) 质量部门的责任2.3 Responsibility for Production Activities 生产作业的职责2.4 Internal Audits (Self Inspection) 内部审计(自检)2.5 Product Quality Review 产品质量审核3. PERSONNEL 人员3.1 Personnel Qualifications 人员的资质3.2 Personnel Hygiene 人员卫生3.3 Consultants 顾问4. BUILDINGS AND FACILITIES 建筑和设施4.1 Design and Construction 设计和结构4.2 Utilities 公用设施4.3 Water 水4.4 Containment 限制4.5 Lighting 照明4.6 Sewage and Refuse 排污和垃圾4.7 Sanitation and Maintenance 卫生和保养5. PROCESS EQUIPMENT 工艺设备5.1 Design and Construction 设计和结构5.2 Equipment Maintenance and Cleaning 设备保养和清洁5.3 Calibration. 校验5.4 Computerized Systems 计算机控制系统6. DOCUMENTATION AND RECORDS 文件和记录6.1 Documentation System and Specifications 文件系统和质量标准6.2 Equipment cleaning and Use Record 设备的清洁和使用记录6.3 Records of Raw Materials, Intermediates, API Labeling and Packaging Materials原料、中间体、原料药的标签和包装材料的记录6.4 Master Production Instructions (Master Production and Control Records)生产工艺规程(主生产和控制记录)6.5 Batch Production Records (Batch Production and Control Records)批生产记录(批生产和控制记录)6.6 Laboratory Control Records 实验室控制记录6.7 Batch Production Record Review 批生产记录审核7. MATERIALS MANAGEMENT 物料管理7.1 General Controls 控制通则7.2 Receipt and Quarantine 接收和待验7.3 Sampling and Testing of Incoming Production Materials 进厂物料的取样与测试7.4 Storage 储存7.5 Re-evaluation 复验8. PRODUCTION AND IN-PROCESS CONTROLS 生产和过程控制8.1 Production Operations 生产操作8.2 Time Limits 时限8.3 In-process Sampling and Controls 工序取样和控制8.4 Blending Batches of Intermediates or APIs 中间体或原料药的混批8.5 Contamination Control 污染控制9. PACKAGING AND IDENTIFICATION LABELING OF APIs AND INTERMEDIATES原料药和中间体的包装和贴签9.1 General 总则9.2 Packaging Materials 包装材料9.3 Label Issuance and Control 标签发放与控制9.4 Packaging and Labeling Operations 包装和贴签操作10. STORAGE AND DISTRIBUTION.储存和分发10.1 Warehousing Procedures 入库程序10.2 Distribution Procedures 分发程序11. LABORATORY CONTROLS 实验室控制11.1 General Controls 控制通则11.2 Testing of Intermediates and APIs 中间体和原料药的测试11.3 Validation of Analytical Procedures 分析方法的验证11.4 Certificates of Analysis分析报告单11.5 Stability Monitoring of APIs 原料药的稳定性监测11.6 Expiry and Retest Dating 有效期和复验期11.7 Reserve/Retention Samples 留样12. VALIDATION .验证12.1 Validation Policy 验证方针12.2 Validation Documentation 验证文件12.3 Qualification 确认12.4 Approaches to Process Validation 工艺验证的方法12.5 Process Validation Program 工艺验证的程序12.6 Periodic Review of Validated Systems 验证系统的定期审核12.7 Cleaning Validation 清洗验证12.8 Validation of Analytical Methods 分析方法的验证13. CHANGE CONTROL 变更的控制14. REJECTION AND RE-USE OF MATERIALS.拒收和物料的再利用14.1 Rejection 拒收14.2 Reprocessing 返工14.3 Reworking 重新加工14.4 Recovery of Materials and Solvents 物料与溶剂的回收14.5 Returns 退货15. COMPLAINTS AND RECALLS 投诉与召回16. CONTRACT MANUFACTURERS (INCLUDING LABORATORIES)协议生产商(包括实验室)17. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS 代理商、经纪人、贸易商、经销商、重新包装者和重新贴签者17.1 Applicability 适用性17.2 Traceability of Distributed APIs and Intermediates已分发的原料药和中间体的可追溯性17.3 Quality Management 质量管理17.4 Repackaging, Relabeling, and Holding of APIs and Intermediates原料药和中间体的重新包装、重新贴签和待检17.5 Stability 稳定性17.6 Transfer of Information 信息的传达17.7 Handling of Complaints and Recalls 投诉和召回的处理17.8 Handling of Returns 退货的处理18. Specific Guidance for APIs Manufactured by Cell Culture/Fermentation用细胞繁殖/发酵生产的原料药的特殊指南18.1 General 总则18.2 Cell Bank Maintenance and Record Keeping 细胞库的维护和记录的保存18.3 Cell Culture/Fermentation 细胞繁殖/发酵18.4 Harvesting, Isolation and Purification 收取、分离和精制18.5 Viral Removal/Inactivation steps 病毒的去除/灭活步骤19. APIs for Use in Clinical Trials 用于临床研究的原料药19.1 General 总则19.2 Quality 质量19.3 Equipment and Facilities设备和设施19.4 Control of Raw Materials 原料的控制19.5 Production 生产19.6 Validation 验证19.7 Changes 变更19.8 Laboratory Controls 实验室控制19.9 Documentation 文件20. Glossary 术语1. INTRODUCTION 1. 简介1.1 Objective 1.1目的This document is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the quality and purity characteristics that they purport, or are represented, to possess.本文件旨在为在合适的质量管理体系下制造活性药用成分(以下称原料药)提供有关优良药品生产管理规范(GMP)提供指南。
Qualification protocol of Compressed air system压缩空气系统验证方案
Qualification protocol of Compressed airsystem压缩空气系统确认方案Prepared by起草:Date日期:Reviewed by审阅:Date日期:Approved by批准:Date日期:Table of contents目录1.0 Instruction引言 (3)1.1 Summarize概述 (3)1.2 State of Equipment设备的基本情况 (3)2.0 Purpose验证目的 (4)3.0 Responsibility验证职责 (4)3.1 Validation team验证小组 (4)3.2 Equipment department设备部 (5)3.3 Quality department质量部 (5)4.0 Validation scope验证范围 (6)5.0 Validation content验证内容 (6)5.1 Installation Qualification(IQ)安装确认 (6)5.2 Operation Qualification(OQ)运行确认 (9)5.3 Performance Qualification性能确认 (10)5.4 Re-validation and re-validation period拟定再验证及验证周期 (11)5.5 Conclusion 验证方案结论 (12)6.0 Approval of validation protocol验证方案最终批准 (12)Content正文1.0 Instruction引言:1.1 Summarize概述:Compressed air met Criteria was provided for manufacturing process produced from air compressor in this Compressed air system and cleaning treated. 本压缩空气处理系统是通过空压机制取的压缩空气,经过净化处理后为生产工艺提供合格的洁净空气。
制药厂压缩空气系统清洁验证方案(完整版)
1. 引言1.1 验证方案名称:压缩空气系统的清洁验证方案1.2 验证方案编号:MC-Y03-0021.3 验证方案审批表1.4验证小组成员及职责验证方案会签页目录1.引言2.验证目的3.验证使用文件4.验证范围5.验证条件6.清洁灭菌的方法与检验合格的标准7.验证实施8.清洁过程QA监控9.验证实施时间进度安排及周期10.验证实施过程的整理、验证报告的书写11.原始记录保存地点12.附件压缩空气系统的清洁验证方案1.概述×××××制药有限公司设有前处理车间、前处理提取、口服固体制剂三个生产车间,生产片剂、胶囊剂、颗粒剂、丸剂、胶剂、散剂、煎膏剂七个剂型。
根据工艺要求,生产车间共设4个用气点,温度要求均为常温。
用气点分别为:多功能中药灭菌、干燥制粒、高效包衣、铝塑泡罩包装等。
根据工艺要求,设计产气量为2.4m3/min,排气压力0.7MPa,所有单元设备的结构制作、材料及采用的管件阀门均采用304不锈钢,满足GMP的要求;整个系统全自动运行;工作流程合理,保证系统出气气质稳定,确保系统运行安全可靠。
气体质符合《中国药典》2000年版药用气体的要求。
2.验证目的验证压缩空气系统清洁消毒规程的效果。
“药品生产质量管理规范”明确要求压缩空气系统的制备、储存和分配应能防止微生物的滋生和污染,储罐和输送管道所用材料应无毒、耐腐蚀。
管道的设计和安装应避免死角、盲管。
本系统的管道和阀门材料均采用304不锈钢,管道的连接应用氩弧焊接。
本公司的压缩空气分配系统材料均采用304不锈钢材料,连接采用氩弧焊避免管道接头的死角滋生微生物。
3.验证所需文件臭氧消毒灭菌操作规程压缩空气系统的标准操作规程压缩空气系统的标准清洁规程4.验证范围压缩空气系统的清洁验证5.验证条件5.1设备条件5.1.1压缩空气系统为完好系统。
5.2人员条件5.2.1在岗人员均经过GMP知识,微生物常识、药品管理法及其实施细则、产品质量法等法律法规的培训。
洁净压缩空气的验证
洁净压缩空气的验证范例2-1洁净压缩空气系统验证方案目录1.概述2.验证目的3.验证所需的相关文件4.验证的内容及过程4.1预确认4.2安装确认4.3运行确认4.4性能确认5.结果分析与评价6.再验证周期的确定7.验证时间的安排8.验证结果及批准注:企业在编制文件时应加入页码1. 概述1.1洁净压缩空气系统采用空气压缩机产生压缩空气,经过冷冻干燥机去处水分,通过三级空气过滤去除粒、油分,达到洁净空气净化,并在使用点终点根据需要安装除菌过滤器。
使用压缩空气的洁净度等合工艺用气的要求。
1.2系统工艺流程1.3本方案仅适用于洁净压缩空气系统的验证。
2. 验证目的2.1对空压系统的设计及本型号设备的可靠性进行评估。
2.2对空压系统的设备、管道安装能否达到生产工艺要求作出确认。
2.3通过对空压机所提供的压缩空气检测,以评价空压系统的产气量能否满足生产要求;通过对过滤装置过滤后的空气检测,以确定安装的合理性和适用性;确定过滤后的压缩空气无油、无尘,微粒在规定范围内,空气洁净度达到相应级别净化要求;过滤装置的过滤效果达到生产工艺所规定的要求。
3. 验证所需的相关文件4.验证的内容及过程4.1确认4.1.1工艺设计对设备的要求能连续不断地为气动生产设备及通气检验提供稳定的洁净的气源;并能根据空气的使用情况自动调节产气量,保证工作气源压力稳定可靠;过滤后的空气符合相应洁净级别的要求。
4.1.2系统配置情况检查空气压缩机、储蓄罐、过滤器管道等系统配置是否符合生产工艺要求?4.1.3售后维修服务维修服务单位:xxxx有限公司详细地址:联系人:联系电话:4.2安装确认4.2.1目的:保证安装质量达到设备安装验收规范要求。
4.2.2检查系统管道的安装情况;管道、阀门材质是否符合要求。
4.2.3检查确认系统所有仪器、仪表的校验情况。
4.2.4过滤器完整性测试:检测各过滤器完整性及各使用点上除菌过滤器的除菌性能。
4.2.5异常情况及处理所有设备安装均应在供货商技术人员指导下进行,如发现异常情况应与供应商人员一起研究,及时处理,并记录异常情况现象、处理措施、处理结果。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
GMP and Functional Risk Assessment for Compressed AirGMP and Functional Risk Assessment for Compressed Air Page 1 of 15DOCUMENT HISTORYThis risk assessment serves as GMP and Functional Risk Assessment for Systems, as well as traceability matrix between requirement,potential risk, and measure to control risk (e.g. specific test specification, additional requirement to mitigate risk, SOP).Risk Assessment ProcedureStep 0 – Approval Cover Page and Document History▪The section “Risk Assessment Work Session Attendance” will be used to record work session number, list of attendees, and the work session date.▪After completion of the Risk Assessment (before executing the specific measures) the Risk Assessment will be initially approved (section “Assessment”).▪In case that the approved Risk Assessment will be revised, the initial approval of the Risk Assessment is obsolete and the revised Risk Assessment requires a new approval. The Revision Number must be adapted accordingly.▪If - all defined measures and tests are completed and- in all rows the cell “Measures completed” is assessed “Yes”then the Risk Assessment is finally approved in the section “Final Assessment Approval”.Step 1 – Description of the current process / work flowGMP and Functional Risk Assessment for Compressed Air Page 2 of 15Fill out columns “Source Document”, “Function” and “Reverse Function”▪Source Documents typically encompass the System URS, block diagram, and/or functional description, but related documents must also be considered. For example, if the 21 CFR Part 11 assessment demonstrates that the system must comply with Part 11, a row must be added in thecorresponding GMP/FRA to ensure traceability to this GMP critical requirement. Other System level “umbrella” documents, egg AutomationURS and/or Electrical URS that contain Critical GMP requirements that apply to many systems, must either have their own GMP/FRAassessments, or the GMP critical requirements traced in each System level GMP/FRA.Step 2 –Risk Assessment [column “Risk Assessment”]Probability Ratingo Low (L): Due to the design failures may not occur. The design is well known and often used.o High (H): The design is new and not well known. There is a high probability that failures occur.Impact Rating▪Which impact has the described failure, independently of the probability rating?o Low (L): No impact to the product quality.o High (H): Impact to productProbability of Detection▪Which probability of failure detection is given? Is it possible to detect the failure immediately or latest during Quality Control/batch release?o High (H): The failure will be detected immediately.o Low (L): The failure can not be detected immediately. The failure may not be detected during Quality Control tests.GMP criticality▪Assess the risk in regard to product quality and patient safety. Note: GMP criticality is not the same as GMP-relevance. GMP relevance will not be changed by application of specific measures and control. GMP criticality is reduced by proper design and control of the process. Forexample, sterilization process failures (e.g. temperature not reached during sterilization) have high GMP criticality, but proper design of thesterilizer and control of the process with sensors reduces GMP criticality. However, although GMP criticality has been reduced, the GMPrelevance of a compliant sterilization cycle remains unchanged.o High (H): There is an impact on product quality and/or patient safety and/or the impact is not under control / not acceptable.o Low (L): There is insignificant impact on product quality and/or patient safety and/or the impact is under control / acceptable.▪Record the unique URS ID number in the Reference Document column for all GMP crit ical requirements (marked “H”).▪For each GMP critical requirement, insert the specific URS requirement in the Function column.GMP and Functional Risk Assessment for Compressed Air Page 3 of 15Step 3 – Definition of specific measures to mitigate risks (columns Measures, Action)The main measures are, but not limited to:▪Definition of additional design requirements (e.g. in URS, FS) to mitigate risk▪Definition and execution of additional, specific IQ, OQ and PQ tests▪Generation of specific Standard Operating Procedures (SOPs)▪Specific operational procedures▪Additional sensors for process monitoring and control▪Calibration of quality relevant/critical sensors▪Cleaning validation▪Safety measures and arrangementsDefine and document the responsible person and the due date for the specific measure.Step 4 – Risk Assessme nt [column “Risk Assessment considering defined measures”]Assessment in view of the successful execution of all defined measures to mitigate risks.Apply the same rating as in Step2:Probability RatingThe probability of occurrence if all defined measures are implementedImpact RatingThe impact of an event usually remains the same independently of the defined measures.Probability of DetectionThe probability of detection of an event if all defined measures are implementedGMP-criticalityThe GMP-criticality must be low, otherwise additional measures must be defined.Step 5 – Execution of specific measuresGMP and Functional Risk Assessment for Compressed Air Page 4 of 15The execution and documentation of specific measures are traced and controlled via test specifications, list of critical sensors, preventive maintenanceplans, and/or open item lists.Document titles and revision should be documented in column “Test Documentation / Traceability / Reference” under the corres ponding point (DQ, IQ,…). In case of to many documents or title of document to long it is possible to include a reference (e.g. a reference to a Test Specification overview)in the column.The execution completion should be documented with initials and date in the column “Action / Responsible Due Date”.Step 6 – Measures completedAfter documented execution of all specific measures and tests to mitigate risks, the completion and closure is checked and confirmed in the last cellof each row.Step 7 – Risk Assessment CompletionAfter all measures of the entire analyses are completed (step 6 for all rows) the Risk Assessment will be finally approved on the cover page (section“Final Assessment Completion”).GMP and Functional Risk Assessment for Compressed Air Page 5 of 15GMP and Functional Risk Assessment for Compressed Air Page 6 of 15GMP and Functional Risk Assessment for Compressed Air Page 7 of 15GMP and Functional Risk Assessment for Compressed Air Page 8 of 15GMP and Functional Risk Assessment for Compressed Air Page 9 of 15GMP and Functional Risk Assessment for Compressed Air Page 10 of 15GMP and Functional Risk Assessment for Compressed Air Page 11 of 15GMP and Functional Risk Assessment for Compressed Air Page 12 of 15GMP and Functional Risk Assessment for Compressed Air Page 13 of 15GMP and Functional Risk Assessment for Compressed Air Page 14 of 15GMP and Functional Risk Assessment for Compressed Air Page 15 of 15。